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Abstract 
In the last years there have been studies about the therapeutical effects of calcitriol. 
The use of this compound in therapeutical quantities has been associated with calcemic 
effects which has been made infeasible the use of this molecule as a therapeutic drug. Due 
to these secondary effects the investigation of new analogs has increased. 
Therefore, the objective of this project is the development of new calcitriol analogs.  
Docking studies showed some promising values to three analogs, which are the final 
molecules that we wanted to synthesize. In this work has been tried the synthesis of the CD 
ring precursors of these analogs using two different methods. One of the methods was done 
in Porto and the other one in Spain.  
The three analogs that we proposed to synthetize are enantiomerically different from 
the calcitriol molecule, and so, one of the main difficulties in their synthesis is obtaining the 
enantiomerically pure CD ring precursors. Consequently, in this thesis we had focused in 
resolution strategies, like esterification with a chiral molecule, to obtain the corresponding 
diastereomeres, the use of enzymes as a catalyst of this esterification, and the asymmetric 
Sharpless epoxidation.  
Most of these strategies did not worked and so, it is necessary more studies in order 
to obtain the wanted analogs.  
 
Key words 
Vitamin D, Calcitriol analogs, CD bicyclic ring, Wittig reaction, ylide, Alcohol resolution, 
Sharpless asymmetric epoxidation 
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Resumo 
 Nos últimos anos tem-se investigado os efeitos terapêuticos do calcitriol. A utilização 
deste composto em quantidades terapêuticas tem sido associada a efeitos calcémicos que 
inviabilizam o uso desta molécula como fármaco. Devido a esses efeitos secundários, a 
procura de novos análogos tem aumentado. 
 Portanto, o objetivo deste projeto é o desenvolvimento de novos análogos de 
calcitriol. 
 Os estudos de Docking feitos mostraram alguns valores promissores para três 
análogos, que são as moléculas finais que se pretende sintetizar. Neste trabalho tentou-
se fazer a síntese dos precursores do biciclo CD desses análogos usando dois métodos 
diferentes. Um dos métodos foi realizado no Porto e o outro na Espanha. 
 Os três análogos que propusemos sintetizar são enantiomericamente diferentes 
da molécula do calcitriol e, portanto, uma das principais dificuldades na sua síntese é a 
obtenção dos precursores do biciclo CD enantiomericamente puros. Portanto nesta tese o 
foco foi o estudo de estratégias de resolução, como a esterificação com uma molécula 
quiral, para obter os diastereoisomeros correspondentes, o uso de enzimas como 
catalisadores dessa esterificação e a epoxidação assimétrica de Sharpless. 
 A maioria destas estratégias não funcionou e, portanto, são necessários mais 
estudos para obter os análogos desejados. 
 
Palavras Chave 
Vitamina D, Análogos do Calcitriol, Biciclo CD, Reação de Wittig, Ileto, Resolução de 
álcoois, Epoxidação assimétrica de Sharpless 
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Introduction 
1. Vitamin D  
1.1. Vitamin D chronology. 
The classic bone disease, rickets was first described around 1645 and 1660 by Dr. 
Daniel Whistler1. Prior to 1789, the treatment of rheumatism and rickets, was carried out by 
the consumption of cod liver oil (known for the great amount of vitamin D)2. Only in 1824 D. 
Schütte proposed cod liver for the treatment of rickets1.  
In 1914 Casimir Funk wrote an article in which he describes that the rickets must 
occur only when certain substances in the diet are lacking, and these specific substances 
were present in good breast milk and in cod liver oil. In 1919 Kurt Huldschinsky showed that 
the ultraviolet rays, from a mercury lamp, could improve rickets in children3. Also in 1921 an 
article was published concluding that exposure to sunlight could treat rickets in children by 
testing five children with this disease to sunlight 4 5. 
Vitamin D has two distinct forms, ergocalciferol (vitamin D2) and cholecalciferol 
(vitamin D3) (Fig.1). The vitamin D2 is produced by fungus and its discovery was first 
published in 1930 by Askew et al. They extracted vitamin D2 from a mixture of plant sterols 
and discovered that this compound was active in the healing of the rickets. Also, this group 
has been successful in isolating vitamin D and in determining the structure of the vitamin D2 
(ergocalciferol)6.  
 
Fig. 1- Chemical structure of Cholecalciferol (vitamin D3) and ergocalciferol (vitamin D2). 
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Vitamin D3 (cholecalciferol) is synthesized in our organism and is a secosteroid (9,10 
secosteroid)1. The structure of this vitamin is influenced by the structure of its precursor, pro-
vitamin D3 (7-Dehydrocolestrol). This precursor has four rings, a, b, c and d (Fig.2). The 
similarity of the two structures is because provitamin D3 forms the vitamin D3 by a 
photochemical reaction. During the transformation in vitamin D3, the ring b opens and forms 
the triene system7 (Fig.2). In 1936 Windaus and Bock determined the structure of the 
precursor synthetized in the skin 8-9.  The confirmation that vitamin D3 is synthetized in the 
skin was given by Esvelt et al. and Holick et al., by the chemical identification of both vitamin 
D3 and provitamin D3 in the skin10-11.  
 
Fig 2- Structure and nomenclature of the pro-vitamin D3 and the vitamin D3. 
Later in 1938, it was established that the UV light is necessary to synthetize vitamin 
D in rachitic rats12. Since then vitamin D has showed that can be used for the treatment of 
other diseases, having therefore pharmacologic potential. 
1.2. Vitamin D system 
Our skin has a lipophilic hormone known as 7-dehydrocholesterol (pro-vitamin D3), 
and when exposed to the UV radiation is transformed into previtamin D3. This molecule is 
then transformed in Vitamin D3 (cholecalciferol) with the heat of our skin. Because vitamin 
D3 is inert in our body it as to be activated. To became active this vitamin has to be 
metabolized first in the liver, by the enzyme 25-hydroxylase, and then in the kidney, by the 
enzyme 25-OH-D-1α-hydroxylase, becoming in this way the active form of vitamin D, the 
calcitriol13 (Scheme 1). 
                                               
1 Secosteroid is a steroid molecule with a broken ring.  
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Scheme 1 Metabolism of vitamin D in our body.  
In order to be metabolized, the vitamin D3 must be transported in the blood by the 
vitamin D binding protein. This binding protein bounds to the vitamin D (both ingested and 
skin synthetized) in the circulatory system, which will take the vitamin to the liver to be 
metabolized14  
In addition to the biosynthesized calcitriol it can, also be, found in food in low 
amounts. Foods rich in this vitamin are oily fish, like salmon, tuna, sardines, and oils from 
fish liver like cod, and f sun-exposed mushrooms. Some foods, like margarine, yogurt, infant 
formula, butter, cheese and breakfast cereals are now fortified with vitamin D. The vitamin 
D obtained from dietary sources has to be firstly integrated into chylomicra and then 
transported by the lymphatic system into the venous system14.  
After the formation of calcitriol, it will bind to the VDR receptor, since this molecule 
has a great affinity to this receptor. This binding will lead to an increase of intestinal 
absorption of calcium and phosphor 15. To regulate the amount of calcitriol is necessary the 
enzyme 24-hydroxylase that degrades both 1,25-(OH)2D3 and 25-OH-D3, by the catalysis of 
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the side chain oxidation. This hydroxylation can start on the C23 or on the C24. In the C23 
pathway, exists a hydroxylation at C23 and C26 to get as final product the 1,25-(OH)2D3-
26,23-lactone. In the oxidation by the C24 pathway, it occurs a cleavage of the sidechain, 
obtaining the calcitroic acid. This last pathway occurs in five steps. After this process these 
more hidrossoluvel catabolites can be excreted16-18.  
 
1.3. Function and biological activity of calcitriol  
After being ingested or synthetized the calcitriol is transported by the VDBP (Vitamin 
D Binding Protein) and then binds to the VDR receptor (this binding is responsible for the 
biological activity). The VDB protein besides the transportation of the vitamin D metabolites 
is responsible for the protection of calcitriol, increasing its half-life in the serum19. 
1.3.1. VDR Receptor 
The VDR receptor belongs to the large nuclear receptor superfamily. This 
superfamily of nuclear receptors is activated by lipophilic hormones such as steroids, 
retinoids, thyroid hormones and vitamin D. These hormones are potent regulators of 
development, cell growth and differentiation, homeostasis and organ physiology. Due to 
their lipophilicity they can pass through the membrane and bind to the nuclear receptor20. 
This receptor is widely distributed across the body tissues.  
The human VDR receptor is a 427 amino acid peptide and has various domains. The 
first domain is the N terminal (A/B region), then the second domain, the C region a DNA 
binding domain (DBD), the third domain appears in a flexible hinge region (D region) and 
the last is the E or E/F domain, where is the ligand binding domain (LBD) 21-22.  
1.3.1.1. DNA binding domain 
The DBD domain is highly conserved, and consists in two similar modules, 
containing zinc fingers structures. In each zinc finger the zinc atom is individually 
coordinated in a tetrahedral way and is stabilized by four highly conserved cysteine residues. 
These two zinc fingers are apparently structurally similar, but they differ because they have 
a different chirality of the residues that coordinate the zinc atom in each module. Moreover, 
these two structures have a different function. The first zinc finger is responsible for the 
binding of specific DNA to the VDRE (vitamin D response elements) and the second zinc 
finger serves as the site for heterodimerization of the VDR to the RXR 21, 23.  
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1.3.1.2. Ligand binding domain 
This domain contains the VDR binding pocket, which is responsible for the interaction 
between the ligand (vitamin D) and the receptor. In the end of the C-terminal there is an 
activation domain known as AF- 2, which is important for the binding of coactivators and 
corepressors 23. When the ligand binds to the LBD, it will induce a change in the 
conformation of the AF-2 helix, this change will allow the recruitment of coactivators 24.  
The overall fold of the VDR LBD is like other nuclear receptors, this LBD has 13 α 
helices that forms three “sandwich” layers and has three stranded β sheets. This domain 
goes through major changes when a ligand is bound. When the ligand is bound to the 
receptor the helix 11 gets the same direction as the helix 10, and the helix 12 (H12) changes 
their position to seal the binding cavity of the LBD. The residues of the H12, Val-418 and 
Phe-422, make two van der walls connections with the methyl group of the ligand. The 
position of this helix is maintained by two polar interactions and several hydrophobic 
interactions. There are some residues that interact with the ligand and are important to 
stabilize the position of H12 such as Val-234, Ile-268, His-397 and Tyr-401. The ligand biding 
pocket is coated by, mostly, hydrophobic residues and the cavity has a volume of 697Å3, 
which only 56% is occupied by the ligand. The space of the cavity that isn´t occupied by the 
ligand is used by two water molecules near the position 2 of the A ring. This additional space 
can accommodate ligands with the methyl group at the position 2 (shows an increase in 
affinity of 4-fold greater than the natural ligand). When connected to the VDR receptor the 
calcitriol molecule is in its active conformation. In this conformation, the A ring of the calcitriol 
is in a β chair conformation and the 1-OH and the 3-OH are in equatorial and axial 
orientations. The triene system connecting the A and C rings is adjust in hydrophobic 
channel sandwiched between, on one side by Ser-275 and Trp-286, and the other side by 
Leu-233. The hydroxyl group at the position 1 forms two hydrogen bonds with Ser-237 (helix 
3) and Arg-274 (helix 5) and the hydroxyl group at the position 3 makes two hydrogen bonds 
Ser-278 (helix 5) and Tyr-143. The Arg-274 is bounded to water molecules, making a water 
channel. The 25-hydroxyl group forms two hydrogen bonds with His-305 (helix 6—7) and 
His-397 (helix 11). The aliphatic chain in the position 17 of the D ring is in an extended 
conformation that is parallel to the C13-C18 bond and is surrounded only by hydrophobic 
residues24-25.  
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Fig. 3 -Calcitriol interaction with binding pocket of VDR. Image given by Julian Loureiro. 
1.3.2. Calcitriol mechanisms of action 
As written before, the calcitriol is necessary to regulate various process in the 
organism. These processes happen in two ways: by the genomic mode, in which the 
calcitriol interact with the VDR receptor which then interacts with the genome, and by a 
nongenomic way. These two mechanisms of action have different binding pockets in the 
receptor. In 2004, it was found a rapid response binding pocket, known as VDR-AP (vitamin 
D receptor – alternative pocket)26. The other binding pocket, the most known, is the genomic 
response binding pocket (described above), VDR-GP (vitamin D receptor - genomic poket). 
These two pockets partially overlap.  
1.3.2.1. Genomic mechanism 
. In the genomic process when the ligand, calcitriol, binds to the receptor the VDR-
GP interacts with the RXR to make a heterodimer. This heterodimer then binds to the 
receptor VDREs (vitamin D response elements) and will lead to an up or down-regulation of 
these genes. When the ligand binds to the LBD this will induce a change in the conformation 
of the AF-2 helix which allow the recruitment of a coactivator. 
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This type of mechanism is responsible for the genomic functions of vitamin D, such 
as intestinal calcium and phosphate absorption signaling. The genomic mechanism 
generally takes a few hours to days to manifest and can be blocked by a inhibitor27-28 (Fig. 
4).  
 
Fig. 4-Genomic mechanism of the calcitriol. 
First the vitamin D binding protein transports the calcitriol to the cell. Then inside the 
cytosol the calcitriol will connect to the VDR and make a heterodimer with the RXR. This 
heterodimer will bind to VDRE and will connect to a coactivator that binds to an RNA 
polymerase. Then the target genes transcription will occur, which will lead to specific 
functions like mineral homeostasis. 
1.3.2.2. Nongenomic mechanism 
The non-genomic mechanism, known as the rapid-response mechanism, acts much 
faster than the genomic one. This mechanism can take from various seconds to an hour27. 
In this mechanism the calcitriol binds to a VDR associated with a caveolae of the plasm 
membrane, instead of binding to a nuclear localized VDR. This biding will result in the 
activation of one or more second messenger systems involving G-protein-coupled receptors, 
phosphatidylinositol-3’-kinase (PI3K), protein kinase C (PKC) or modulate the genomic 
responses (crosstalk). This type of mechanism can lead to an opening of voltage-gated Ca2+ 
and Cl- channels, stimulate exocytosis, rapid intestinal Ca2+ absorption, rapid pancreas 
insulin secretion or activation of MAP kinase, linked to cell differentiation, and 
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phosphoproteins. This type of responses mediated by the VDR has been only studied in in 
cell culture27-28. 
1.3.3. Biological activity 
The active form of vitamin D, calcitriol, is fundamental to the homeostasis of both 
calcium and phosphorous.  
 To occur the mineral homeostasis is required the involvement of the kidney, 
parathyroid gland, intestine and bone. When exists a decrease in serum calcium the 
parathyroid glands sense it. In order to restore these levels, this gland will secrete/synthetize 
the parathyroid hormone (PTH). The PTH hormone sends a signal to the kidney to activate 
the CYP27B1 (1α-hydroxylase) transcription, which will result in the production of 1,25-
(OH)2D3.  Calcitriol will then bind to the VDR receptor and increase the intestinal calcium 
and phosphate absorption (in the duodenum calcitriol stimulates the calcium channels 
(TRPV6) which leads to an increase in Ca2+ absorption). Both low concentrations of calcium 
or phosphate in the serum lead to the liberation of PTH hormone29. Calcitriol also induces 
the synthesis of phosphaturic hormone FG23 in bones. This hormone suppresses the renal 
synthesis of calcitriol by inhibiting the expression of CYP27B1. This hormone also lowers 
the serum phosphate levels by inhibiting renal phosphate reabsorption21, 30.  
In osteoblasts, the vitamin D is involved in the formation of osteoid matrix and 
mineralization. The vitamin D is also responsible for the regulation of cellular proliferation 
and differentiation. These grown-regulation actions of the vitamin D are being studied for the 
potential roles in the treatment of cancer, regulation of the immune system and autoimmune 
disease and cardiovascular diseases. These cellular growth-regulating activities are visible 
in the skin, so this antiproliferative and anti-inflammatory effects of the calcitriol are being 
studied for the treatment of psoriasis21.  
1.4. Diseases and therapeutical applications 
Calcitriol is important for the regulation of various mechanisms in the organism, so, 
an unbalanced level of calcitriol can lead to diseases. Vitamin D deficiency can lead to some 
diseases such as rickets, higher risk of fractures and osteoporosis, cardiovascular diseases, 
hypertension, diabetes, autoimmune diseases, and cancer, such as colon cancer30. 
The excess of vitamin D can be harmful too; one of the major problems associated 
is hypercalcemia. Hypercalcemia, high levels of calcium in the blood serum, can lead to 
calcification of the soft tissues, which can cause organ failure and dead 31. 
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Due to the biological activity of the calcitriol, described above, the calcitriol molecule 
has been used as a model for the development of new drugs. These new drugs could act in 
different therapeutical areas such as oncology, bone disease, skin, neuroscience, 
hematopoietic system, hormone secretion and auto-immune diseases. The major problem 
associated with the use of calcitriol as a drug is the hypercalcemic effects30.  
2. Calcitriol analogs  
To prevent the calcemic effects associated with the calcitriol treatment, some studies 
had been done with the objective of finding some new analogs. Here the focus will be in 
analogs with the same basic structure of the calcitriol molecule. Besides this kind of analogs, 
there exist calcitriol mimetics that don’t have any basic structural features of the calcitriol 
molecule but that show some of the activities of the calcitriol molecule. These calcitriol 
mimetics had been developed in order to enhance some specific properties such as their 
anti-proliferative and immunomodulatory capacities32. 
2.1. Structure function relationship of vitamin D 
Is necessary to understand the relations between the structure and the 
corresponding biological activity. This type of information is important to know what we can 
change in the structure and what is necessary to maintain the desirable effects. In the 
structure of calcitriol there are three different parts that can be distinguished in the structure: 
the central rigid CD-bicyclic ring portion, the flexible side chain connected to CD ring at C17 
and the flexible seco-B, A ring system.  
2.1.1. Conjugated triene (seco-B ring) and A ring 
After the side chain modifications, the A ring modification has been the most studied. 
In the A ring hydroxyls, the change of the 1α-hydroxyl group configuration for β-
hydroxilated 25(OH)D showed that the analog gets essential inactive. Substituting the 
hydroxyl group by a fluoro group showed an enormous reduction in the biological activity. In 
other studies that eliminated the portion 10,19, did not showed lack of function, in fact exists 
a commercial analog known as Zemplar that don’t have this portion. This analog has less 
calcemic effects and retain the capacity of the calcitriol molecule in suppressing PTH in 
chronic renal failure diseases. 
The analog is only able of binding to the VDR receptor, if it shows a trienic system in 
which the diene bonds align with the tryptophan residue of the VDR33.  
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Some known attempts of alter this system by changing the 5,7 portions of the system 
and replacing the carbons 6 and 7 by nitrogen or doing catalytic reduction, destroyed the 
activity of the molecule. This shows the importance of the triene system in the activity of the 
calcitriol molecule and analogs34. 
2.1.2. C/D ring 
To study the importance of the CD ring, some studies were made. One of them, in 
which a calcitriol analog was synthetized without the CD group, the analog did not show any 
activity. Most of the studies made in which the CD ring was absent, the analogs didn’t have 
activity and the ones that showed some activity had a low activity and it isn’t known if these 
compounds would “survive” once they appear in the circulation. Therefore, the current 
evidence shows that the removal of the CD ring leads to a complete elimination of the vitamin 
D activity. However, the methyl group at the position 18 had showed little influence in the 
biological activity of the vitamin D34. 
 To increase the time of the analog in the organism is necessary to make analogs 
that inhibit the molecule catabolism. Some studies shown that functional changes in the side 
chain could influence the rate of the side-chain catabolic oxidation. The incorporation of a 
16-ene modification was enough to alter the ligand-enzyme interaction and cause significant 
decrease in the rate of the side chain catabolic oxidation35. 
2.1.3. Side chain 
The first generation of calcitriol analogs, were modified in the side chain of the 
calcitriol due to practical reasons, preserving the A-ring and the 25-OH group. Therefore, 
there are many analogs with various modifications at the side chain. 
When the side chain is reduced to an ethyl group, the receptor binding is reduced, 
and the in vivo activity disappears. With an increase in the number of carbons at the side 
chain, the activity of the analog also increases. However, the longer the side chain the 
greater the calcemic effects. So, for a good vitamin D activity a full side chain and the 25-
hydroxyl group is important.  
The alteration of the C20 configuration to the unnatural S-configuration showed an 
increase in the biological activity and an increase in bone resorption activity. Alteration in 
the C21, C26 and C27 has been studied in vivo. These eliminations change both intestinal 
calcium absorption and bone calcium mobilization 34.  
Strategies such the modification of the C-H group by a C-F group showed a decrease 
in the catabolism, this is justified since the C-F bond is much stronger and so, less easily 
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broken. The only disadvantage is that the analogs made with this alteration are similar to 
the calcitriol molecule, and, therefore, showed the same toxic hypercalcemia. An insertion 
of a sulfone group in the carbon 26 had shown an increased antiproliferative and 
transcriptionally activity and low calcemic activity 35.  
2.2. Analogs with clinical interest 
Some of the calcitriol analogs with clinical interest are shown in the Fig. 5. These analogs 
are used in treatment of autoimmune diseases such psoriasis and eczema and other most 
commonly associated like osteoporosis.  
 
Fig. 5- Some of the calcitriol analogs with clinical interest36-37. 
Rocaltrol is the calcitriol molecule sold by the pharmaceutical Hoffman-La Roche. 
The analogs of this molecule available are the Alfacalcidiol, Doxercalciferol, Paricalcitol, 
Mexacalcitol, Tacalcitol, Calcipotriol and Eldecalcitol. The Alfacalcidiol, known also as, one 
alpha, is used for management of hypocalcemia, secondary hyperparathyroidism, and renal 
osteodystrophy38. The Doxercalciferol, known as Hectoral, and the Maxacalcitol, known as 
22-oxacalcitriol, are used in the treatment of secondary hyperparathyroidism 39,40. 
Paricalcitol, known as Zemplar, is used for the treatment of secondary hyperparathyroidism 
associated with chronic kidney disease. The Tacalcitol analog, also known as Bonalfa, and 
the Calcipotriol, known as Daivonex, are used for the treatment of psoriasis. The last one, 
Eldecalcitol, also known as Edirol, it’s sold in Japan for the treatment of osteoporosis37. 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
12 
 
 
2.3. Synthesis of calcitriol 
In this section are explored some of the synthetic methods used to obtain analogs of 
calcitriol, or to synthetize the calcitriol molecule.  
2.3.1. Synthesis of triene unit and A ring 
The actual synthetic approaches to obtain some calcitriol analogs are based on 
convergent methodologies in which a fragment containing an A-ring is attached to a CD 
fragment41. To make the coupling between the A ring and the CD ring exists three 
approaches, a, b and c. These types of methodologies and approaches are presented in 
Scheme 2. 
 
Scheme 2 - Different methods used to obtain the calcitriol or analogs. 
● Horner Wittig coupling 
 
Scheme 3– Horner-Wittig coupling method to form calcitriol (Hoffmann-La Roche approach). 
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A first approach to this reaction was made by Lythgoe in 1975.This was a Wittig-
Horner reaction between the lithium anion of the allylic phosphine oxide (generated by the 
treatment of the A ring phosphine oxide with n-butyllithium) and the CD-ring Windaus-
Grundmann ketone42. This approach was further improved by the Hoffmann-La Roche 
group, to achieve the first total synthesis of calcitriol 43. 
 The coupling of A ring with the CD ring is obtained in one step at low temperature 
and takes just 1 hour. Then it is deprotected and these two reactions have an overall yield 
of 90 %.  
Below is represented the A ring synthesis developed by this laboratory. This 
synthesis is one of the most efficient total synthesis of the 1α-hydroxy A-ring phosphine 
oxide.  
 
Scheme 4 - Hoffman-La Roche approach to synthetize the A ring. 
This 15-steps procedure has an overall yield of 21%. This synthesis starts from the 
naturally occurring (S)-(+)-carvone, a, that goes through an regio and stereoselective 
epoxidation, b, then this epoxide reacts to form an ester epoxide, that is cleaved and 
esterified, c, then an stereoseletive oxidative cleavage of the isopropenyl side chain is done, 
d, and the hydroxyl groups protected. The E-ester is isomerized to the Z-ester and with more 
4 steps the phosphine oxide is obtained42, 44.  
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● Lythgoe coupling 
This reaction was first described by Lythgoe in 197145 and consists in the coupling of an 
enantiomerically pure A-ring enyne with a CD-ring 9-chloro ketone through acid workup. The 
precalciferol is then obtained by semihydrogenation of the acetylene bond, using a Lindlar 
catalyst. This approach gave an overall yield of 22 %.  Later, in 1980, Okamura made 
another approach.  
 
 
Scheme 5- Lythgoe method to synthetize the calcitriol molecule using Mourino approach. 
Only in 1986, Mourino and his group made another improvement to the Lythgoe’s 
approach by using instead of the CD-ring ketone a CD-ring vinyl triflate46. The Mourino 
approach is described above, Scheme 5, and it is the best version of enyne coupling. In this 
approach the synthesis of the CD-ring 9- chloro ketone is eliminated (this synthesis has a 
low yield and requires 7 steps), and the formation of undesired isomers in the coupling is 
not significant42. 
The synthesis of the A ring is showed below, and it is used an Okamura approach- 
This procedure has an overall yield of 37%47.  
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Scheme 6- Okamura’s approach of the A ring synthesis. 
In this synthesis first occurs the epoxidation of S-(+)-carvone to give cis-carvone 
epoxide, b. Then lithium acetylide is added, to afford the propargyl alcohol, c. The hydroxyl 
group is acetylated and occurs an ozonolysis of the isopropenyl side chain followed by a 
direct acetylation and an in situ Criegee rearrengement to afford the key diacetate, d.  The 
SmI2-promoted reductive elimination of d and concomitant ring opening of the epoxide to 
afford e42, 47. 
● Trost coupling 
 
Scheme 7- Trost method to synthetize the calcitriol molecule. 
This new method for the calcitriol synthesis was described in 1992 by Trost48. This 
approach is a one pot reaction and uses the Pd-catalyzed alkylative cyclization that closes 
the A ring and forms the bond that connects the CD ring unit with the acyclic unit, this acyclic 
unit, is the precursor for the A ring. This reaction has an overall yield of 52%42. 
In the Scheme 8, it is represented the synthesis of the acyclic unit, precursor of the 
A ring.  
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Scheme 8- Trost approach for the A ring precursor synthesis. 
 This synthesis has a yield of 20 %. In this reaction, the enantiomerically pure enyne 
was obtained by using a Sharpless epoxidation with a 46 % yield42.   
● Carbocyclization-Suzuki coupling 
 
Scheme 9- Suzuki–Miyaura method to synthetize the calcitriol molecule. 
This reaction was developed at Mourino’s laboratory and has a yield of 72%. This 
coupling has only two steps. This aproach is characterized by a highly stereoselective 
intramolecular cyclization of an enol triflate (A ring precursor), followed by a in situ Suzuki–
Miyaura coupling of the resulting palladium intermediate with an alkenyl boronic ester (CD 
ring and side-chain)49.  
 The synthesis of the precursor of the A ring is below, Scheme 10. This method has 
a total yield of 29%.  
 
Scheme 10- Mourino's approach for the A ring precursor synthesis. 
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The synthesis of the A ring precursor starts with the l-carvone, this compound is 
epoxidized and forms a protected epoxide. Then the oxidative cleavage of the epoxide is 
performed with periodic acid in diethyl ether. The final step is the conversion of the aldehyde 
into the desired vinylic triflate50.  
2.3.2. Enantioselective syntheses of the CD-ring  
The synthesis of the CD rings of the calcitriol molecule (trans-hydrindane system) is 
difficult. The major problem is the synthesis of the trans-stereocenter at the ring junction51. 
Some strategies were developed to synthesize this moiety.  
● Hoffman-La Roche approach  
 
Scheme 11- Hoffman La-Roche approach for the CD-ring synthesis. 
This approach was done by the Hoffman- La Roche laboratory52. The starting 
material on this approach is a keto acid that was originally synthesized from an enedione53. 
In this process the starting material is hydrogenated stereoselectivity to form the 
corresponding trans-hydrindane derivative. 
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● Lythgoe approach 
 
Scheme 12- Lythgoe's approach for the CD-ring synthesis. 
Lythgoe was the first to develop a total synthesis of the Inhoffen- Lythoe diol54. In this 
approach the two starting materials, the orthoester and the allylic alcohol reacts, through a 
Claisen rearrangement, to give the Ɣ-lactone. This compound is then hydrolyzed and 
methylated to the corresponding ester. Then a cyclization occurs after a reduction to give 
the desired Inhoffen-Lythgoe diol44. 
 
● Trost approach 
 
Scheme 13- Trost approach for the CD-ring synthesis 
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This synthetic method was developed by Trost and has a yield of 8%. In this 
approach the synthesis starts with a sulfone, that undergoes two alkylation’s, posterior 
desulfonylation and protection of the alcohol. This compound is then oxidized, using the 
Baeyer-Villiger oxidation, giving the lactone. The lactone is reduced to a diol and the primary 
alcohol is protected. Then, by a Claisen rearrangement the trans-ring junction is formed. 
Later by the removal of the THP protection group the trans-hidrindane system is formed. 
This last product undergone some other steps like, hydrogenation and oxidation to obtain 
the expected alcohol.  
 
● Mourino’s newest approach  
 
Scheme 14- Mourino's approach for the CD-ring. 
This approach was developed by Mourino’s laboratory and has a total yield of 8%. 
The most important steps in this reaction are: The Sharpless epoxidation reaction, needed 
to obtain the desired alcohol, the Pauson-Khand reaction, super important for the cyclization 
of the compound to obtain the desired bicyclic ring, and the cuprates reaction, important to 
insert the methyl group in CD junction55.  
3. Bioavailability 
In drug development is important to ensure that the “new drug” is absorbed to ensure 
its therapeutical effect. The definition of bioavailability is the fraction of drug that gets 
unchanged to the circulatory system. The bioavailability of the drug is associated with the 
administration route, is assumed that the intravenous route has a bioavailability of 100 %. 
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The administration routes used are intravenous, intramuscular, subcutaneous, oral, rectal, 
transdermal and inhalation.  
The new drug must pass through 4 important steps, absorption, distribution, 
metabolism and excretion (ADME). The performance in this steps will indicate the reliability 
of the new drug.56  
To improve the probability of a drug being accepted as a new drug, the docking 
studies, that evaluate the interactions of the future drug with the corresponding receptor, 
and other studies such the evaluation of the properties of the molecules have been done 
with the objective to improve this first process of “finding” the most adequate molecule  
In 1997 were found by Lipinsky 5 rules that evaluate the druglikeness of a drug. 
These rules predict that a drug is more likely to show low absorption when exists more than 
5 hydrogen bond donors and more than 10 hydrogen bond accepters, has a molecular 
weight higher than 500 Da and the LogP is bigger than 5. These rules evaluate the capacity 
of a molecule to pass through the membrane lipid bylayer57.   
The use of this rules makes the found for new possible drugs easier, but at the same 
time can eliminate some compounds that would be important. These rules don’t work for all 
the drugs known. Some drugs have molecular weights higher than 500 Da and can be orally 
absorbed  
New studies were done that showed exceptions to this rule, and these rules have 
been enlarging over the years.58.  
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Objectives  
In this work, it is proposed the synthesis of precursors of the vitamin D analogs that, 
according to the previous docking studies may have a good interaction with the vitamin D 
receptor. The main objective in this work is the synthesis and resolution of synthetic 
precursors of the enantiomerically pure CD bicyclic rings, using different approaches.   
The retrosynthetic plan for this work is represented in the Scheme 15. 
 
Scheme 15- Retrosynthetic plan for the synthesis of the analogs. 
 This thesis was done in collaboration with the “Faculdad de Quimica da Universidade 
de Santiago de Compostela” thanks to the Erasmus + program.  
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Results discussion  
1. Docking 
In order to know the most adequate analogs to be synthetized was important to do 
some docking studies. These docking studies were done with the help of my investigation 
group and with the help of the computational chemistry/biochemistry investigation group of 
the “Faculdade de Ciências da Universidade do Porto”.  
 
Fig. 6- Calcitriol analogs studied. 
 The molecules chosen for these docking studies are represented in the Fig. 6. The 
analog A differ from the original calcitriol molecule in the junction of the hydrindane system, 
where it has the opposite configuration. Then, in this analog lack’s a methyl group in the 
lateral chain and appears a new double bond. The other difference is that the lateral chain 
of the analog A has 6 carbons.  
The other two molecules, B and C, differ from the calcitriol, mainly in the bicycle CD. 
The calcitriol molecule shows a 6,5 bicyclic ring but in these two analogs the bicycle appears 
with a 5,5 bicyclic ring and a double bond. The lateral chain has 7 carbons. The great 
difference between the analogs B and C is the configuration of the CD ring.  
For this docking study we used the crystal structure of the nuclear receptor for vitamin 
D (without the flexible insertion domain) bound to its natural ligand, calcitriol, made by Dr. 
Moras and his team in 200024.  
The molecules were drawn using ChemDraw v16.0 and undergone an MM2 
minimization in the ChemDraw 3D v16.0. This last step was done to obtain the initial 
conformations of the molecules. This process was repeated to the calcitriol molecule. 
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To evaluate the interactions between the analogs with the binding pocket of the 
vitamin D receptor the program GOLD was used 59. This software attributes a punctuation 
corresponding to the interactions of the small molecule with the aminoacids of the binding 
pocket of the receptor. The obtained results are compared with the punctuations obtained 
for the original ligand, the calcitriol. The punctuation for the calcitriol is considered 100%.  
1.1. Docking results for the calcitriol analog A 
The docking punctuation for this analog was 95%.  Which means that the molecule 
doesn’t fit so good as the original, but still fits good in the binding pocket of the vitamin D 
receptor. In the Fig. 7 is represented the interactions of the analog 1 with the aminoacids of 
the VDR binding pockets, and the overlap with the calcitriol molecule. 
 
Fig. 7- Representation of the analog A interacting with the VDR binding pocket, A, and the overlap of the analog with the 
calcitriol molecule, B. 
1.2. Docking results for the calcitriol analog B 
The docking punctuation for this analog was 103%. Which means that the molecule 
fits even better than the original ligand in the binding pocket of the vitamin D receptor. In the 
Fig. 8 it is represented the interactions of the analog with the aminoacids of the VDR binding 
pockets, and the overlap of the calcitriol molecule with the analog.   
A 
B 
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Fig. 8- Representation of the analog B interacting with the VDR binding pocket, A, and the overlap of the analog with the 
calcitriol molecule, B. 
1.3. Docking results for the calcitriol analog C 
The analog C had a docking punctuation of 104%. This better punctuation is probably 
due to the configuration of the analog, since its configuration is much more similar to the 
calcitriol molecule. In Fig. 9 is represented the analog principal interactions with the VDR 
binding pocket and the overlap of the analog with the calcitriol molecule.  
 
B 
A 
Fig. 9- Representation of the analog C interacting with the VDR binding pocket, A, and the overlap of the analog with the 
calcitriol molecule, B. 
A B 
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1.4. Analogs results comparison  
The major difference between these tree analogs is that the analogs B and C make 
different interactions with the aminoacids when compared with the analog A and the original 
ligand. The hydroxyl group at C25 in the analog A and calcitriol, interacts with the 
aminoacids Serine 237 and Arginine 237, and the other hydroxyl group at C3 position 
interacts with the serine 278 and Tyrosne 143. In the analogs B and C happen the opposite, 
the hydroxyl group at C25 interacts Serine 237 and Tyrosine 143, the other hydroxyl group 
interacts with the other two aminoacids. The analogs B and C differ from each other only in 
the configuration but show the same interactions with the aminoacids. However, these two 
analogs show different docking punctuation, being the punctuation better for the analog C. 
The analog A, is much more similar to the calcitriol molecule, but shows the lower 
docking punctuation, this can be due to the double bound in the lateral chain that require a 
larger lateral chain, when compared with the original ligand, in order to make good 
interactions with the both histidine’s. The other major difference between both molecules is 
the configuration of the bicycle CD, as we can observe in figure 7 that gets a total different 
torsion when compared with the calcitriol molecule. 
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2. Strategy and synthetic plan 
The work presented in this thesis aims to synthetize 3 different calcitriol analogs Fig. 10.  
Therefore, in this project we have tried to synthetize the 3 different precursors presented in 
the Fig. 11, by using Mourino’s approach. 
 
 
Fig. 10 - Molecule of calcitriol and the wanted analogs. 
 
 
Fig. 11- The corresponding precursors of the previous analogs that we tried to obtain. 
For the synthesis of the analogs of these bicyclic rings we started with the 
corresponding alcohols. For the precursor a we started with the 5-hexyn-1-ol to obtain the 
6,5 bicyclic ring.  For the precursors b and c started with the 4-pentyn-1-ol to obtain the 5,5 
bicyclic ring. 
In this project we tried different approaches to obtain the precursors. The first 
strategy to be explained in this section is the strategy done in Porto. The main route used in 
this strategy had already been done in Santiago de Compostela60. In Porto we tried different 
strategies to be able of resolving the wanted molecules. This strategy is shown in Fig. 12. 
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Fig. 12- Synthetic strategy used in Porto to obtain the three wanted precursors. 
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In this method the synthesis starts with the alcohols 5-Hexyn-1-ol and the 4-Pentyn-
1-ol, 1 and 14. These alcohols were first protected to improve the final yield of the reaction, 
4 and 17. After the protection, the compounds 4 and 17 were oxidized to the aldehydes 5 
and 18. These aldehydes, 5 and 18, were alkylated using a Grignard reagent and the 
alcohols 6 and 19 were formed. These alcohols were also protected to undergo the first 
attempt of resolution, the isocyanate resolution method. This resolution method failed, so, 
we had to deprotect the alcohols 7 and 20, to obtain again the 6 and 19 alcohols. After 
having the alcohol deprotected we tried different resolution methods, such as enzymes, 
esterification with chiral molecules, and a Sharpless epoxidation.  
 
 The next strategy explained in this section is the strategy done in Santiago de 
Compostela This strategy has been done before, just for the analog 1, and showed to be 
very promising61. The synthetic plan used is in the Fig.13. 
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Fig. 13- Synthetic plan used in Santiago de Compostela to obtain the wanted precursors. 
 In this last method the starting materials were the same, the alcohols 5-hexyn-1-ol 
and the 4-pentyn-1-ol, 1 and 14. Like in the other method, and for the same reasons, the 
alcohols were first protected, 4 and 17. Then the compound 4 undergone a one-pot reaction 
of oxidation followed by a Wittig reaction which formed the 11 ester. The ester 11 was 
reduced with DIBAL-H, to form the corresponding allylic alcohol. The next step would be a 
Sharpless reaction to form the compound 13. 
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3. Work done in Porto 
3.1. Synthesis of the alcohols 4 and 17 
The protection of the commercial compounds is needed to lower the volatility of these 
alcohols, and so increasing the yield. The use of this protecting group in particular (the 
benzyldimethylsilane) and the effects in the volatility of these compounds was studied before 
by our research group.  
In order to obtain the two wanted alcohols, it was used the commercial compounds 
5-hexyn-1-ol and 4-pentyn-1-ol. First, we had to protect the hydroxyl group, to become 
possible the protection of the triple bound. The hydroxyl group was first protected with 
dihydropyran in the presence of pyridinium p-toluenesulfonate and dichloromethane as 
solvent. Then was necessary a strong base to deprotonate the triple bond and becoming 
available for the bond of the protecting group. As protecting group was used 
benzyldimethylsilane. This protection reaction was done in THF and at -78°C. Then the 
protected alcohol was deprotected using a catalytic amount of p-toluenesulfonic acid, this 
reaction was done in the presence of methanol62, Scheme 16.  
 
Scheme 16- Protection of the alcohols 1 (n=1) and 14 (n=0) to obtain the alcohols 4 (n=0) and 17 (n=1). 
The total yield obtained for the synthesis of these two alcohols was high, for the 4 
the yield was 104 % and for the 17 was 85%. The observed high yield for the alcohol 4 can 
be justified by the existence of solvent. These two alcohols are very volatile, so we didn’t 
concentrate that much, to ensure that the compound wasn’t lost. 
These compounds were then identified by NMR (1H, 13C and DEPT). 
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Fig. 14- Chemical shifts(ppm) for the compound 4. 1H NMR- H and 13C NMR-C. 
 By the analysis of the proton spectrum of the compound 4, we can see the existence 
of some peaks, such as the chemical shift at 0.08 ppm that corresponds of the two methyl’s 
attached to the silane group. The existence of this peak and the peaks that correspond to 
the phenyl group 7.20 – 7.03 ppm show that the protection of the triple bond was achieved. 
 By the analysis of the carbon spectrum we can see the peaks that correspond to the 
triple bond at 108.65 and 83,26 ppm and the peak that corresponds to the carbon of the 
phenyl group with a chemical shift of 139.27 ppm.  
 
 
Fig. 15- Chemical shifts(ppm) for the compound 17. 1H NMR- H. 
By the analysis of the proton spectrum of the compound 17 we can see the same 
chemical shift, of the compound 4, at 0,11 ppm corresponding to the two methyl’s attached 
to the silane group, and by the analysis of the all spectrum, all the protons are identified 
showing that the protection of this molecule, was also achieved. 
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3.2. Synthesis of the alcohols 6 and 19 
In order to synthetize the two alcohols 6 and 19 we first oxidized the alcohols 4 and 
17 to obtain the aldehydes 5 and 18. To oxidase the alcohols were used pyridinium 
chlorochromate 63 and sodium acetate. The obtained 5 and 18 aldehydes were alkylated 
using a Grignard reagent, Vinylmagnesium Bromide, to obtain the alcohols 6 and 1964, 
Scheme 17. This last reaction was done using as solvent THF and at -78°C. 
 
Scheme 17- Reactional steps for the synthesis of the 6 (n=1) and 19 (n=0) alcohols. 
For these two reactions the overall yield was 67 % for the 6 alcohol and 71% for the 
19 alcohol. 
The obtained products were then identified by NMR (1H, 13C and DEPT). 
 
Fig. 16- Chemical shifts(ppm) for the compound 6. 1H NMR- H and 13C NMR-C. 
By the analysis of the proton spectrum of the compound 6, the most important peaks 
that show that the compound 6 was obtained are at the chemical shift 5.82 ppm, and 5.24-
5.13 ppm, corresponding to the new double bond formed, positions C2 and C1 respectively.  
  By the analysis of the carbon spectrum we can see the peaks that correspond to the 
new double bond shows chemical shifts of 141,14 and 114,97 ppm. These peaks show that 
the compound 6 was formed. 
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Fig. 17- Chemical shifts(ppm) for the compound 19. 1H NMR- H and 13C NMR-C. 
Similarly to the peaks found for the compound 6 we can identify by analysis of the 
proton spectrum of the compound 19, the most important peaks that show that the 
compound 19 was formed, such as the peaks with a chemical shift of 5.86 ppm, and 5.27-
5.15 ppm, that correspond to the new double bond formed, positions C2 and C1 respectively.  
  From the analysis of the carbon spectrum we can see the peaks that correspond to 
the new double bond shows chemical shifts of 140,74 and 115,17 ppm. These peaks show 
that the compound 19 was formed. 
 
3.3. Synthesis of the protected alcohols 7 and 20 
After the structures 6 and 19 were confirmed by the RMN, these alcohols were 
protected to be prepared for the next step, the Pauson-Khand reaction.  
The two alcohols were protected with Tert-Butyldimethylsilyl chloride, and imidazole 
and using as solvent dimethylformamide in the reaction of the 6 and dichloromethane in the 
reaction of the 1965. 
 
Scheme 18- Protection of the alcohols 6 (n=1) and 19 (n=0). In the protection of the alcohol 6 was used DMF and in the 
reaction of 7 was used as solvent DCM. 
The yield obtained for the protection of these two alcohols is different. The yield of 
the protection of 6, where it was used as solvent DMF, was 84% and the yield associated 
with the protection of 19, using as solvent DCM, was 64%. This difference seems to be 
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associated with the solvent used, thus showing that for this type of protection DMF is the 
solvent of choice, like in the protocol used for this reaction65. 
These compounds were then identified by NMR (1H, 13C and DEPT). 
 
Fig. 18- Chemical shifts(ppm) for the compound 7. 1H NMR- H and 13C NMR-C. 
 By analysis of the proton spectrum of the compound 7, the most important peaks 
that show that the alcohol was protected were the chemical shifts at 0,05 ppm, 
corresponding to the methyl in the silane group and the peak at 0.92 ppm corresponding to 
tert-Butyl group.  
  By the analysis of the carbon spectrum we can see the peaks that correspond to the 
protecting group, with chemical shifts at 18.41 ppm, that corresponds to the quaternary 
carbon, and 26.05 ppm that corresponds to the tert-Butyl group. 
 
 
Fig. 19- Chemical shifts(ppm) for the compound 20. 1H NMR- H and 13C NMR-C 
From the analysis of the proton spectrum of the compound 20, the most important 
peaks that show that the alcohol was protected were the chemical shifts at 0,05 ppm, 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
35 
 
 
corresponding to the methyl in the silane group and the peak at 0.91 ppm corresponds to 
the tert-Butyl group.  
By the analysis of the carbon spectrum we can see the peaks that correspond to the 
protecting group with chemical shifts at 18.38 ppm, corresponding to the quaternary carbon, 
and at 26.05 ppm that corresponds to the tert-Butyl group. 
3.4. One of the strategies used for the resolution of the alcohol 7 
One of the first strategies used to in order to separate the racemic mixture and get 
one of the stereoisomers wanted it was trying the separation of the compounds only after 
cyclization. First, we made the cyclization by using the Pauson-Khand reaction, then we 
reduced the obtained ketone to the wanted alcohol. This alcohol would then react with a 
chiral isocyanate which would allow the separation through silica column. This last part of 
the resolution was done in my research group 66. However, this resolution attempt didn’t 
work.  
3.4.1. Synthesis of the ketone 9 
To obtain the ketone 9, we used a Pauson-Khand reaction using as starting material the 
protected alcohol 7. In order to make this reaction, we used the protocol from the Santiago 
research group55. The yield obtained for the Pauson-Khand reaction was 67%.  
 
 
Scheme 19- Cyclization of the protected alcohol 7 to obtain the ketone 9. 
The Pauson-Khand reaction was first discovered in 1973 by lhsan U. Khand and 
Peter L. Pauson et all67, and is the reaction of dicobalt octacarbonyl complexes with alkenes 
to form cyclopentenone. This reaction is characterized by a [2 + 2 + 1] cycloaddition in which 
a triple bond, a double bond and carbon monoxide form a cyclopentenone. So, this type of 
reaction leads to the formation of three new bonds and, in this case, two cycles since this 
reaction is a intramolecular version. 
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This type of reaction can be accelerated using promoters, in this case the promoter 
used was NMO. The promotors can facilitate the coordination of the alkene to the cobalt 
atoms. The mechanism proposed for this reaction is in the Scheme 2068. 
 
Scheme 20- Cyclization of the bicycle68-69. 
First occurs the formation of a complex with the alcohol 7, in which the initial 
octacarbonyl complex loses 2 CO ligands. Then occurs the alkene coordination with this 
complex in which occurs the loss of a CO molecule. This step is the rate-determining step 
and in order to accelerate this process it is used promoters. Then the olefin is inserted into 
a Co–C bond forming a cobaltacycle. Then an insertion of a CO molecule occurs and a 
carbonyl group is formed. Finally, the release of dicobalt hexacarbonyl occurs, and the 
wanted ketone 9 is formed 70. 
The obtained compound was then analyzed by NMR (1H, 13C, DEPT). 
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Fig. 20- Chemical shifts(ppm) for the compound 9. 1H NMR- H and 13C NMR-C 
 
From the analysis of the proton spectrum of compound 9, we can see some peaks 
that correspond to hydrogens in the bicyclic ring and to the peaks that correspond to the 
protecting group. 
  From the analysis of the carbon spectrum it is possible to identify the peaks that 
correspond to the used protecting groups. It is also possible to observe the chemical shifts 
of the carbons in the bicyclic ring, such as two quaternary carbons at the position 3a and 3 
with a chemical shift of 189.4 ppm and 136.4 ppm respectively. The other important peak is 
the one that corresponds to the carbonyl at position 2, with a chemical shift of 213,1 ppm. 
3.5. Deprotection of alcohols 6 and 19 
Since we didn’t succeed in our attempt to perform the quiral resolution the molecules 
using an isocyanate, we deprotected the remaining alcohols 7 and 20. This deprotection 
was done using a catalytic quantity of p-TsOH in methanol.   
 
Scheme 21- Deprotection reaction to obtain the alcohols 6 and 19. 6 (n=1), 19 (n=0). 
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This deprotection had a yield of 89% for the 19 alcohol. The 6 had a yield too big, 
above 100%, which means that it should have solvent, can be explained by the fact that this 
deprotection didn´t needed purification, the TLC showed only one spot. 
These compounds were identified by NMR (1H, 13C and DEPT). 
The spectra from these two compounds were similar to the presented in the section 
3.2.  
3.6. Chiral resolution  
We attempt to perform the resolution of the obtained alcohols using another two 
resolving agents. Then we tried it using enzymes ( Novozyme 435, and Amano enzymes). 
Our last attempt of resolution used a Sharpless asymmetric epoxidation. 
3.6.1. Resolution using resolving agents 
In this attempt we esterified the compound 6 with Z-L-alanine hydroxysuccinimide 
ester to form the wanted diastereomers, scheme 22. This resolution method didn’t work.  
 
Scheme 22- Attempt of alcohol 6 resolution using z-Ala-OSu. 
The other method used is shown in the Scheme 23. In this attempt we tried to make 
a diastereomer with a more common rigid structure, and thus, making the alcohol easier to 
separate. In this strategy we used, as the rigid structure the phthalic anhydride. That would 
be esterified with the alcohol 19, and then using the chiral reagent, (R)-(+)-1- 
Phenylethylamine, the diastereomers should be obtained  
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Scheme 23- Attempt of alcohol 19 resolution. 
 
The proposed mechanism for this reaction is shown in Scheme 24.
 
Scheme 24 - Mechanism used to esterify the alcohol in order to obtain diastroreoisomers. 
In the mechanism the alcohol attacks the phthalic anhydride in the carbonyl group, 
which will lead to an opening of the anhydride. Then the base, in this case the DIEA, takes 
the proton of the alcohol. With the addition of the TBTU to the reaction, an activated ester is 
formed, that will then react with the chiral molecule added, in this case the (R)-(+)-1-
phenylethylamine.  
This reaction didn’t work. We saw some spots in the TLC, but after separation and 
RMN analysis we concluded that this reaction didn’t worked. 
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3.6.2. Resolution method using different enzymes 
The kinetic resolution has been used as a green alternative when compared with the 
others resolution methods. Enzymes show a high enantioselectivity towards an ample range 
of secondary alcohols. This enantioselective activity can be used to predict which is the 
enantiomer of a secondary alcohol that reacts faster in a lipase catalyzed reaction, see 
Scheme 25. These reactions can be performed with high regio- and enantioselectivity under 
mild reaction conditions72.  
 
Scheme 25- Enzyme binding regions. 
The characteristic enantioselectivity found with lipases occurs because lipases 
display alcohol binding regions with a larger hydrophobic pocket and a medium one. So only 
one of the enantiomers will have a better fit in the binding region, and so, only one of the 
enantiomers will react73. 
The enzyme resolution method was done using three different enzymes. The first 
one was done with Novozyme 435. The other two attempts were done with two different 
AMANO enzymes, the PS and the AYS. The reaction used for these three enzymes was the 
same and performed with the same quantities and solvent. The reaction catalyzed by the 
three enzymes was the transterification of the S-enantiomer with ethenyl acetate (Scheme 
26).  These procedures were done according to the literature71.  
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Scheme 26 - Attempt of alcohol 19 resolution using three different enzymes, Novozym 435, AYS AMANO and PS AMANO.  
After 35 hours of reaction, only with Novozyme 435 could be found the wanted 
product. With the other two enzymes we could not observe the formation of any product. 
The compounds obtained in the reaction with the Novozyme 435, were analyzed first by 
NMR (1H, 13C, DEPT). 
 
Fig. 21- Chemical shifts(ppm) for the compound 23. 1H NMR- H and 13C NMR-C 
The analysis of the proton spectrum of the compound 23, showed that the alcohol 
was acetylated, with a chemical shift at 2,07 ppm, corresponding to the methyl of the acetyl 
group, and a peak at 5,33 ppm corresponding to the hydrogen at C3.  
 From the analysis of the carbon spectrum we could confirm the acetylation of the 
alcohol, with a peak at 170.17 ppm corresponding to the carbonyl group.  
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In order to conclude if the alcohol resolution occurred, we analyzed the mixture of 
compounds by HPLC using a chiral column. Therefore, we needed to synthetize first the 
racemic acetylated alcohol by the reaction shown in Scheme 27. Using the same starting 
alcohol 19 and acetyl chloride to esterify the alcohol in the presence of DMAP. 
 
Scheme 27- Esterification reaction of the 19 alcohol.  
 
This reaction had a yield of 89%. The compounds were then analyzed by NMR 
(1H,13C, DEPT), and the spectra obtained was similar to the one obtained with the enzymatic 
catalyze. 
After the synthesis of 23, we had to find the eluent conditions that were able to 
separate both enantiomers. The conditions were studied with the racemic mixture of the 
acetylated alcohol, 23. Then, after we had been able to get the chromatogram peaks well 
resolved (using a eluent of 99% of hexane and 1% of isopropanol and a flow of 0,5 mL/min) 
we used the same conditions to run a sample with the acetylated compound obtained from 
the reaction catalyzed by the enzyme. The chromatograms are displayed in the Fig. 22 and 
Fig. 23. 
 
Fig. 22- Chromatogram obtained for the racemic acetylated alcohols. 
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Peak Retention 
time [min] 
Area Area 
[%] 
1 9,252 14379,146 49,5 
2 10,162 14643,605 50,5 
 Total 29022,751 100,0 
Table 1- Data obtained by the integration of the two peaks of the chromatogram above. 
 
 
 
Fig. 23- Chromatogram obtained for the alcohol acetylated by the Novozyme 435 
Peak Retention 
time [min] 
Area Area 
[%] 
1 8,760 25186,133 49,2 
2 9,490 25998,061 50,8 
 Total 51184,194 100,0 
Table 2- Data obtained by the integration of the two peaks of the chromatogram above. 
Observing the chromatogram in the Fig. 22 and the corresponding table we can see 
two peaks with similar area values. Each peak correspond to an enantiomer, as is expected, 
since the mixture is racemic. 
Observing the chromatogram in the Fig. 23, when the reaction was catalyzed by 
Novozyme 435, we can also see two peaks with similar areas, which was not expected. So, 
we can conclude that this resolution didn’t work. The chromatogram obtained for the 
acetylated alcohol obtained in the reaction catalyzed by the Novozyme 435 showed two 
peaks which means that the enzyme catalyzed the reaction of both enantiomers.  
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3.7. Resolution method using a Sharpless asymmetric 
epoxidation  
This was the last resolution method attempted. We did this epoxidation using as the 
start material the 19 alcohol, and we followed the literature procedure55, 74.  
This last method is known as the Sharpless asymmetric epoxidation. This reaction 
was first reported by K.B. Sharpless and T. Katsukib in 1980 and is characterized by the 
Ti(IV) alkoxide-catalyzed epoxidation of chiral allylic alcohol using a chiral tartrate ester and 
an alkyl hydroperoxide as an oxidant. This reaction is known for the high yields and excellent 
enantiomeric excess 75. 
 
Scheme 28- Resolution of the alcohol 19 using the Sharpless asymmetric epoxidation method. 
 
This reaction was done with an already chiral alcohol 19, so this process was 
necessary only to separate the enantiomers. The epoxidation reaction only occurred with 
one of the enantiomeric alcohols, in this case the R alcohol. Since the other alcohol 21, 
doesn’t react, the separation through a chromatographic column is viable. The (R) alcohol 
only, reacts with the L-(+)- diisopropyl tartrate74. The mechanism of this reaction is shown in 
the Scheme 29. 
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Scheme 29- Mechanism for the Sharpless asymmetric epoxidation. 
 
The first step in this reaction is the exchange of the ligands of Ti(Oi-PrO)4 with the 
Diisopropyl tartrate. After this first complex formation, this will undergo more ligands 
exchange, first with the alcohol that was reacting and then with the tert-Butyl hydroperoxide. 
After the alcohol being epoxidized, it is released to the solution and then TBHP is released 
from the complex to the solution and the first complex is formed again75-76. 
We were not able to confirm this resolution method, we were only able to analyze 
the NMR (1H, 13C and DEPT) spectra. We still need to analyze by HPLC, using a chiral 
column. The obtained alcohol has the same NMR as the one in the section 3.2.  
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4. Work done in Spain 
4.1. Synthesis of the alcohols 4 and 17 
The reactional steps for the protection of these two alcohols were the same used in 
Porto. The principal difference is that at the University of Santiago we did this reaction using 
higher amounts of the commercial alcohols 5-hexyn-1-ol and 4-pentyn-1-ol. In order to 
ensure that we had enough compound for all the steps needed to synthetize the three 
analogs. So, we started with 15 grams of 5-Hexyn-1-ol and 20 grams of 4-Pentyn-1-ol. We 
had some difficulties in the purification of this amounts because of the very long time needed 
for the purification. The reaction of the protection of the triple bond were performed twice for 
each alcohol. 
 
Scheme 30- Reactional steps for the synthesis of the alcohols 4 and 17 (4 for n=1 and 17 for n=0). 
 Due to the high volatility of the products and due to the high quantities of products 
we didn’t concentrate till the compound was dried, in order to ensure the minimum lost 
product possible. Moreover, we only deprotected compound 3, thus maintaining the 16 
protected. We only used the compound 4 in the next reactions. 
4.2. Synthesis of the ester 11 
The ester 11, was synthetized using as starting material the alcohol 4, with a one pot 
reaction, in which the alcohol was first oxidized using TEMPO and then the formed aldehyde 
was esterified using a Wittig reaction. 
 
Scheme 31-Oxidation of 4 alcohol and Wittig reaction to form the ester 11. 
 
This reaction had a yield of 83%:  
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4.2.1. TEMPO oxidation 
In the TEMPO oxidation it is used a catalytic quantity of TEMPO, 2,2,6,6-tetramethyl-
1-piperidinyloxyl, combined with diacetoxyiodobenze (BAIB), this reaction can be done at 
room temperature and using as solvent DCM. Under these conditions the primary alcohols 
can be rapidly oxidized to aldehydes without any noticeable overoxidation to carbonyl 
compounds, thus showing high selectivity. The oxidation reaction of primary alcohols to 
aldehydes is fast, taking about 2 hours77.  
In this case the primary alcohol 4 was oxidized to the corresponding aldehyde. In the 
Scheme 32 is presented the proposed mechanism for this oxidation.  
 
Scheme 32- Proposed mechanism for the oxidation of alcohol 4 using TEMPO77-78. 
 
In this mechanism there is a ligand exchange between the alcohol and the BAIB, this 
exchange leads to the production of acetic acid. This acetic acid will transform TEMPO in 
an oxoammonium ion. Then, the oxidation of the wanted alcohol occurs. When this oxidation 
occurs, the oxoammonium is reduced to hydroxylamine and the alcohol is oxidized to the 
wanted aldehyde. After this process BAIB comes to regenerate TEMPO in order to close the 
catalytic cycle77.  
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
48 
 
 
4.2.2. Wittig reaction 
In 1950 G..Wittig and G. Geissler concluded various studies in which they reacted 
various aldehydes and ketones with several phosphoranes to obtain the corresponding 
olefins.  This reaction consists in the formation of carbon-carbon double bonds (olefins) from 
the carbonyl compounds and the phosphoranes 79. 
 
Scheme 33- Proposed mechanism for the Wittig reaction. 
 In the Wittig reaction the active reagent is the phosphorous ylide, see Scheme 33.  
The stabilized ylide, used in this reaction, reacts with the carbonyl group of the aldehyde in 
a reversible and slow step. This step will form the intermediary betaine. Then the oxygen 
attacks the phosphorous giving rise to another intermediate the oxaphosphetane. This last 
intermediate then breaks down and forms the corresponding E-olefin, 1180. In this case the 
reaction occurred with an aldehyde, which is characterized as a faster reaction. In this 
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reaction the only groups that can react are ketone and aldehydes, the other groups stay 
intact during the reaction. In this reaction we used a stabilized ylide, that forms 
predominantly E-olefins with the aldehydes. The non-stabilized ylides give predominantly Z-
olefins79.  
After reaction, the compound obtained was identified by NMR (1H,13H, DEPT), Fig. 
24. 
 
Fig. 24- Chemical shifts(ppm) for the compound 11. 1H NMR- H and 13C NMR-C 
From the analysis of the proton spectrum of the compound 11 we observed, the most 
important peaks that show that this compound was formed have chemical shifts of 5,84, this 
peak corresponds to the double bond at C2 and the chemical shift at 1,30 ppm that 
corresponds to the methyl group.  
  By the analysis of the carbon spectrum we can see some peaks that confirm the 
formation of the compound 11 such as the chemical shift at 166,69 ppm, that corresponds 
to the carbonyl group.  
4.2.2.1. Phosphorous ylide synthesis (Y) 
The ylide needed for the Wittig reaction was synthetized in Porto. This reaction was 
prepared with ethyl bromoacetate and triphenylphosphine.  
This synthesis was improved in Porto by our research group. Before the reaction 
needed to be performed in toluene and stayed in reflux for 10 hours. The yield of this reaction 
was 60%81. However, using our new approach, this synthesis is done at room temperature, 
and as solvent we use Et2O. The yield obtained in this synthesis was 96%.  
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Scheme 34- Ylide synthesis, new approach. 
The mechanism for this synthesis is presented in the Scheme 35.  
 
Scheme 35- Phosphorous ylide formation. 
Firstly, when the ethyl bromoacetate is mixed with the triphenylphosphine occurs the 
formation of the corresponding phosphonium salt. Then when the base is added, occurs the 
deprotonation of the phosphonium salt which will form the phosphorous ylide79. 
This compound was identified by NMR (1H, 13C and DEPT). 
 
Fig. 25- Chemical shifts(ppm) for the compound Y. 1H NMR- H and 13C NMR-C. 
 From the analysis of the proton spectrum, we can see the existence of some peaks 
with a chemical shift between 7,98 and 7,11 ppm, that by integration show a value of 15. 
These peaks correspond to the three phenyl groups that are attached to the phosphor atom. 
Other important peak has a chemical shift of 2,87 ppm. This peak corresponds to the proton 
of the double bond.  
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 From the analysis of the carbon spectrum we can see the peaks that correspond to 
the double bond, 21,12 and 21,11 ppm, and the peak that corresponds to the carbonyl group, 
that shows a chemical shift of 171,12 ppm.  
 
4.3. Reduction to obtain the alcohol 12 
In order to reduce the ester 11 to the alcohol 12, we used DIBAL-H. In this reaction 
is necessary to use 2 equivalents of DIBAL-H. The first equivalent is used to form the 
aldehyde and the second equivalent is used to form the wanted alcohol, 12. The yield 
obtained for this reaction was 54%. 
 
 
Scheme 36- Reduction of the ester 11 to the alcohol 12. 
The compound was later identified by NMR (1H, 13C and DEPT).  
 
Fig. 26- Chemical shifts(ppm) for the compound 12. 1H NMR- H and 13C NMR-C. 
By analysis of the proton spectrum of the compound 12, the most important peak that show 
that this compound was formed have chemical shift of 1.43 ppm and corresponds to the 
hydrogen of the hydroxyl group. The other important characteristic that showed the 
formation of the alcohol 12 is the lack of some of the peaks that correspond to the molecule 
11. 
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 By the analysis of the carbon spectrum we can see some peaks that confirm the formation 
of the compound 12 such as the chemical shift at 63.85 that corresponds to the carbon at 
the position 1. 
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Discussion and conclusions 
In this work we studied two routes to obtain the same precursors of the 
enantiomerically pure CD bicyclic rings. The first route started but not finished was done in 
Spain. The other route was done in Porto.  
The first route was already started for one of the analogs and showed to be 
promising. Here we follow this route but with higher great amounts of initial reagents. Due 
to time constraints the final precursors were not obtained.  
In Porto we tried some resolution approaches to obtain the enantiomerically pure CD 
bicyclic ring, but most of them failed, the only one that seems to work was the Sharpless 
epoxidation, but we are still waiting for the results. In Porto we wanted to find a more 
practical, faster and green resolution method, since the route developed in Spain showed 
some problems when done with higher amounts of reagents. The route developed in Spain 
needed a lot of purifications and had several steps before getting to the bicyclic ring, which 
was unfeasible because of the high amount off compound needed to follow the whole analog 
synthesis.  
In the route done in Spain the resolution would been done with a Sharpless 
epoxidation reaction. In this reaction, in opposite to the Sharpless reaction done in Porto, 
since the alcohol was a primary alcohol, the reaction would form only one product an epoxide 
with the correct configuration. This way is good to obtain the compound A. Since we only 
wanted the compound with only a configuration.  
In the Sharpless epoxidation done in Porto, the reaction occurred with a secondary 
alcohol, here we could only separate the alcohols. This reaction is much slower. And only 
one of the enantiomers reacts forming the epoxide. This reaction has a low yield compared 
with the Sharpless reaction with the primary alcohol. This reaction is better and more efficient 
for the synthesis of the analogs B and C. Since we needed both enantiomers. The bigger 
problem with this method is that the Sharpless reaction needs to react for 21 days, which is 
a long time. The other problem in this method is that we would obtain an alcohol with one 
configuration ready to cyclize and an epoxide with the other configuration, this would need 
to be transformed in the alcohol pretended to be able of cyclize.  
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Future perspectives 
 In order to make the synthesis of these analogs possible is important to find another 
way of resolution that is faster and that have less steps to form the wanted bicyclic ring. This 
would lead to minimum loss of compound synthesized, since to get to the analog is important 
to have the amounts needed for the biological studies.  
So is needed further studies and more time to continue and finish this work.  
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Experimental procedure  
1. Materials and methods 
All sensitive water reactions were done under argon. Glassware used in these 
reactions were previously dried at 100°C, and then were purged with argon. Solvents were 
distilled under argon, using the corresponding drying agents. DCM was dried with P2O5 and 
the THF was dried with potassium. Other solvents used were dried with molecular sieves 
4Å. 
The solution of nBuLi (dissolved in Hexane, Aldrich) was titrated with N-
Benzylbenzamide.  
 Reactions that needed low temperature, were done in refrigerated ketone bath, and 
to measure the temperature was used a Delta OHM thermometer, model HD 9214. Other 
reactions were done at room temperature.  
Thin layer chromatography (TLC), used to follow the reactions and to check the purity 
of the compounds, was performed with aluminum plates coated with a silica gel Merck. The 
revelation of the chromatograms was done with UV irradiation, and using revelators like, p-
Anisaldehyde.  
 All the obtained organic layers were dried using anhydrous Na2SO4. The solvents 
were evaporated in a Buchi rotative rotavapor model 480.  
In the purifications done by flash column it was used silica gel (60 Å, ACROS 
Organics).  
To do the HPLC analyses was used a chiral column, Chiracel, and the HPLC used 
was a Merch HITACHI L-6200 Inteligent Pump, with the detector Merck- Hitachi- L42000 
Uv-Vis Detector. The detection was done at 220 nm. The Software used to obtain the data 
was Clarity - Chromatography SW. Was used as eluents Hexane (CARLO ERBA, ref: 
446903) and 2-Propanol (ROML-SpS, ref: H625). 
NMR spectra was obtained by a spectrometer Bruker BioSpin GmbH (400 MHz for 
1H, and 101 MHz for 13C) belonging to the CMUP. The data was obtained at room 
temperature and compounds dissolved in deuterated chloroform. Was used as reference 
the signal of the solvent CDCl3 with a chemical shift of 7.26 ppm (1H) and 77.16 ppm (13C).  
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The compounds were numbered and named according the IUPAC rules and using 
the ChemDraw v16.0 program.   
The brands of the compounds used are specified below. 
Acetyl chloride Merck, cas - 75-36-5, ref: 114189 
Benzyldimethylsilane Fluorochem, cas -1631-70-5, ref: S00975  
n-BuLi  Sigma, cas - 109-72-8, ref: 230707 
Dicobalt octacarbonyl Sigma aldrich, cas-10210-68-1, ref: 60811 
DIBAL-H  Acros, cas - 1191-15-7 
DIEA  Fluka, cas - 7087-68-5 
(+) DIPT  Aldrich, cas - 2217-15-4, ref: 229180 
DMAP  Aldrich, cas - 1122-58-3, ref: 39405 
Ethyl Bromoacetate Fluorochem, cas - 105-36-2, ref: BR1168 
Sodium acetate cas- 127-09-3 
Lypases PS AMANO, AYS AMANO, NOVOZYME 435 
NMO  Aldrich, cas- 7529-22-8, ref: 224286 
Phenylethylamine  Fluorochem, cas - 3886-69-9, ref: 03743 
PhI(OAc)  Fluorochem, cas - 3240-34-4, ref: 091213 
PPh3   Fluorochem – cas - 603-35-0, ref: 037818 
PPTS   Aldrich, cas - 24057-28-1, ref: 232238 
p-TsOH  Aldrich, cas - 6192-52-5 
TBHP   Aldrich, cas - 75-91-2, Ref: 416665   
TBTU   Bachem, cas - 125700-67-6, Ref: 4013268   
Ti(iPrO)4  Aldrich, cas - 546-68-9  
Vinyl acetate  Aldrich, 108-05-4 
Vinyl magnesium bromide Aldrich, cas - 1826-67-1, Ref: 257257 
Z-Ala-OSu  BACHEM, cas- 3401-36-3, Ref: 40002 
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2. Work done in Porto 
2.1. Synthesis of Ylide  
 
To a round bottom flask under magnetic stirring PPh3 (40 g, 153 mmol, 1 eq.) Et2O 
(≈250 mL) and ethyl bromoacetate (17 mL, 153 mmol, 1 eq.) were added. This mixture was 
left to react for 64 hours. 
The solution was then cooled in an ice bath and the precipitate was filtered with cooled Et2O,  
The obtained precipitated was dissolved in water (≈500 mL). And then was added a solution 
of NaOH 1M (50 mL/10 g of salt).  
The mixture was transferred to a separation funnel and the organic layer was extracted with 
DCM (3*250 mL). The organic layer was dried with sodium sulfate, filtered and concentrated 
in the rotavapor- A yellow oil was obtained. 
The ylide was induced to precipitate adding Et2O. This precipitate was filtered and washed 
with Et2O. A white solid was obtained. This compound was then identified by NMR (1H, 13C, 
13C-DEPT). This reaction had a yield of 96%. 
Aspect: White solid 
ƞ= 96% 
1H NMR (400 MHz, CDCl3) δ 7.98 – 7.11 (15H, m, HPh), 3.96 (s, 2H, HEt), 2.87 (1H, s, Hdouble 
bond), 1.07 (3H, s, HEt). 
13C NMR (101 MHz, CDCl3) δ 171.17 (C, C=O), 133.20 – 128.66 (CPh), [60.44 (CH2), 57.90 
(CH2), CEt], [21.12 (CH), 21.11 (CH), Cdoublebond], [14.88 (CH3), 14.28 (CH3), CEt] 
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2.2. Bicyclic ring 6,5 
2.2.1. Synthesis of 2-(hex-5-yn-1-yloxy) tetrahydro-2H pyran 
(2) 
 
In a dry round bottom flask filled with argon was dissolved 1 (4,63 mL, 42,0 mmol, 1 
eq) in 45 mL of anhydrous dichloromethane. Then were added to the mixture DHP (5,75 
mL, 2,1 mmol, 0,05 eq) and PPTS (5,30, 63,0 mmol, 1,5 eq).  This mixture was left stirring 
for 19 hours at RT. This mixture acquired a yellow color. The reaction was controlled by 
TLC. 
The mixture was transferred to a separation funnel. Then a saturated solution of NaHCO3 
was added. The organic layer was extracted with dichloromethane (3 ｘ20 mL), then 
washed with water (20 mL) and a saturated solution of NaCl (20 mL). The organic layer 
obtained was dried with sodium sulfate and concentrated.  
After the treatment the concentrated mixture was filtrated through SiO2, using as eluent a 
mixture of Et2O/hexane 40%. Then the mixture was concentrated and putted in vacuum. 
Aspect: yellow oil 
RF = 0,80 (20% AcOEt/Hex) 
2.2.2. Synthesis of benzyldimethyl(6-((tetrahydro-2H-pyran-
2-yl) oxy) hex-1-yn-1-yl) silane (3) 
 
In a dry and filled with argon round bottom flask was added 2, from the previous 
reaction, and it was dissolved in THF (40 mL). This mixture was kept at -78°C and was 
slowly added the n-BuLi solution (50 mL, 50,1 mmol, 1,1 eq). The mixture was left stirring 
for 30 minutes. Then SiMe2SiCl (9,82 mL, 54,6 mmol, 1,3 eq) was added. This mixture was 
left stirring for 22 hours at room temperature. The reaction was controlled by TLC.  
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After the solution was cooled to 0°C, 30 mL of a HCl solution of 1 M was added. This mixture 
was extracted with Et2O (3 x 10 mL). Then the organic layer was washed with a saturated 
solution of NaCl. The organic layer was dried with sodium sulfate, filtered and concentrated 
in the rotavapor. This mixture was directly used in the next step. 
2.2.3. Synthesis of 6-(benzyldimethylsilyl)hex-5-yn-1-ol (4) 
 
To a round bottom flask containing 3 methanol and a catalytic amount of p-
toluenosulphonic acid were added. To stop this reaction 30 mL of a saturated solution of 
sodium bicarbonate was added and then this mixture was transferred to a separation funnel. 
The aqueous layer was washed 3 times with 30 mL of ether. The crude was then purified by 
a medium pressure column of 6*15 cm. First the eluent was hexane, then EtOAc/Hexane 
5% and lastly EtOAc/Hexane 10 %. The fractions were collected and then concentrated in 
the rotavapor. This compound was then identified by NMR (1H, 13C, 13C-DEPT). These three 
reactions (1.2.1, 1.2.2 and 1.2.3) had a yield of 104 %. 
Aspect: yellow oil 
Ƞ = 104% (existence of solvent) 
RF = 0,38 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.44 – 6.86 (5H, m, HPh), 3.59 (2H, t, J = 6.2 Hz, H-1), 2.22 
(2H, t, J = 6.8 Hz, H-4), 2.15 (2H, s, CH2Si), 1.98 (1H, s, OH), 1.68 – 1.47 (4H, m, C-3 and 
C-4), 0.08 (6H, s, Si-Me2) 
13C NMR (101 MHz, CDCl3) δ 139.27 (C, CPh), 128.40 (2*CH, CPh), 128.13 (2*CH, CPh), 
124.28 (CH, CPh), 108.65 (C, C-6), 83.26 (C, C-5), 62.20 (CH2, C-1), 31.73 (CH2), 26.52 
(CH2), 24.84 (CH2), 19.66 (CH2), -1.85 (2*CH3, 2CH3-Si). 
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2.2.4. Synthesis of 6-(benzyldimethylsilyl) hex-5-ynal (5) 
 
In a 500 mL flask DCM (200 mL), PCC (18,9 g, 88,0 mmol, 2 eq), NaOAc (4,15 g, 
50,6 mmol, 1.15 eq), and molecular filters (5,03 g) were added. Then the compound 4 was 
added to the mixture and this mixture was left stirring for 2,5 hours at the room temperature.  
The crude obtained was filtered twice by SiO2 and washed with Et2O. The compound was 
dried in vacuum.  
Aspect: Yellow oil 
RF = 0,69 (20% AcOEt/Hex) 
2.2.5. Synthesis of 8-(benzyldimethylsilyl)oct-1-en-7-yn-3-ol 
(6) 
 
To the crude obtained before, compound 5, THF (80 mL) and a solution of 
Vinylmagnesium bromide in THF (66 mL, 66,0 mmol, 1,5 eq.) were added. This mixture was 
left stirring for 15 hours and was controlled by TLC. Then the reaction mixture was 
transferred to a separation funnel and a saturated solution of NH4Cl (80 mL) and a saturated 
solution of NaCl (80 Ml) were added. The organic layer was extracted with Et2O (3*50 mL) 
and then washed with a saturated solution of NaCl (50 mL). Then was dried with sodium 
sulfate, filtered and concentrated in the rotavapor.   
The obtained crude was purified using a SiO2 column (8ｘ6 cm). As eluents were used firstly 
hexane, then 10% of EtOAc/ Hexane and for the last fractions 20% of EtOAc/Hexane.The 
fractions were collected and concentrated in the rotavapor. This compound was then 
identified by NMR (1H, 13C, 13C-DEPT). This reaction had a yield of 67%. 
Aspect: Yellow oil  
Ƞ = 67 %  
RF = 0,57 (20% AcOEt/Hex) 
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1H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (5H, m, HPh), 5.93 – 5.82 (1H, m, H-2), 5.24 (1H, 
dt, J = 17.2, 1.4 Hz, H-1), 5.13 (1H, dt, J = 10.4, 1.3 Hz, H-1), 4.14 (1H, q, J = 6.0 Hz, H-3), 
2.27 (2H, t, J = 6.8 Hz, H-6), 2.18 (2H, s, CH2Si), 1.69 – 1.58 (4H, m, H-4 and H-5), 1.56 
(1H, s, OH), 0.11 (6H,s, Si-Me2). 
13C NMR (101 MHz, CDCl3) δ 141.14 (CH, C-2), 139.39 (C,CPh), 128.51 (2*CH, CPh), 128.24 
(2*CH,CPh), 124.38 (CH, CPh), 114.97 (CH2, C-1), 108.63 (C, C-8), 83.43 (C, C-7), 72.85 
(CH, C-3), 36.10 (CH2), 26.64 (CH2), 24.45 (CH2), 19.89 (CH2), -1.77 (2*CH3, 2CH3-Si). 
2.2.6. Synthesis of benzyl(6-((tert-butyldimethylsilyl) oxy)oct-
7-en-1-yn-1-yl)dimethylsilane (7) 
 
In a dry and filled with argon round bottom flask, with the compound 6, DMF (200 
mL) and Imidazol (6,79 g, 100 mmol, 3,3 eq.) were added. This mixture was left stirring for 
10 minutes.  
To the obtained mixture was added TBSCl (12,39g, 82 mmol, 2,7 eq.). This mixture was left 
stirring until no starting material was observed (4 days). The obtained mixture was 
transferred to a separation funnel and a saturated solution of NaCl (40 mL) and a saturated 
solution of NH4Cl (40 mL) were added. The organic layer was extracted using Et2O., then 
dried with sodium sulfate, filtered and concentrated in the rotavapor.  
The obtained crude was purified by column of SiO2 (8ｘ6 cm). As eluent were used initially 
only hexane and lastly 10 % EtOAc/ Hexane. The compound was then concentrated in the 
rotavapor and identified by NMR (1H, 13C and 13C-DEPT). This reaction had a yield of 84%. 
Aspect: transparent oil 
Ƞ = 84% 
RF = 0,94 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.03 (5H, m, HPh), 5.86 – 5.75 (1H, m, H-7), 5.20 – 5.14 
(1H, m, H-8), 5.08 – 5.03 (1H, m, H-8), 4.14 (1H, q, J = 5.7 Hz, H-6), 2.24 (2H, t, J = 6.5 Hz, 
H-3), 2.18 (2H, s, CH2Si), 1.69 – 1.50 (4H,m, H-4 and H-5), 0.92 (9H,s, t-Bu), 0.10 (6H, s, 
Si-Me2), 0.07 (3H, s, CH3-Si), 0.05 (3H, s, CH3-Si). 
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13C NMR (101 MHz, CDCl3) δ 141.64 (CH, C-7), 139.43 (C, CPh), 128.52 (2*CH, CPh), 128.25 
(2*CH, CPh), 124.37 (CH, CPh), 113.93 (CH2, C-8), 108.92 (C, C-1), 83.16 (C, C-2), 73.49 
(CH, C-6), 37.13 (CH2), 26.69 (CH2), 26.05 (3*CH3, t-Bu), 24.25 (CH2), 20.02 (CH2), 18.41 
(C, C-Si), -1.77 (2*CH3, Si-Me2), -4.23 (CH3, CH3-Si), -4.66 (CH3, CH3-Si). 
 
2.2.7. Synthesis of 8-(benzyldimethylsilyl)oct-1-en-7-yn-3-ol 
(6) 
 
To a 250 mL round bottom flask compound 7 (0,825g, 2,13 mmol, 1 eq.), MeOH (100 mL) 
and p-TSOH (0,02 g, 0,11 mmol, 0,05 eq.) were added. 
The mixture was concentrated in the rotavapor and transferred to a separation funnel. To 
the separation funnel a saturated solution of NaCO3 (50 mL) was added. The organic layer 
was extracted using Et2O, dried with sodium sulfate and concentrated in the rotavapor. The 
compound obtained was pure so wasn’t done a purification. 
The compound was then concentrated in the rotavapor and identified by NMR (1H, 13C and 
13C-DEPT).  
Aspect: transparent oil 
Ƞ = >100% (solvent) 
RF = 0,43 (20% EtOAc/Hexane) 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (5H, m, HPh), 5.93 – 5.82 (1H, m, H-2), 5.24 (1H, 
dt, J = 17.2, 1.4 Hz, H-1), 5.13 (1H, dt, J = 10.4, 1.3 Hz, H-1), 4.14 (1H, q, J = 6.0 Hz, H-3), 
2.27 (2H, t, J = 6.8 Hz, H-6), 2.18 (2H, s, CH2Si), 1.69 – 1.58 (4H, m, H-4 and H-5), 1.56 
(1H, s, OH), 0.11 (6H,s, Si-Me2). 
13C NMR (101 MHz, CDCl3) δ 141.14 (CH, C-2), 139.39 (C,CPh), 128.51 (2*CH, CPh), 128.24 
(2*CH,CPh), 124.38 (CH, CPh), 114.97 (CH2, C-1), 108.63 (C, C-8), 83.43 (C, C-7), 72.85 
(CH, C-3), 36.10 (CH2), 26.64 (CH2), 24.45 (CH2), 19.89 (CH2), -1.77 (2*CH3, 2CH3-Si). 
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2.2.8. Synthesis of 3-(benzyldimethylsilyl)-7-((tert-
butyldimethylsilyl)oxy)-1,4,5,6,7,7a-hexahydro-2H-inden-2-
one (9) 
 
To a dry and filled with argon round bottom flask, was transferred 7 (2,117g, 5,62mmol, 1 
eq.)  and DCM (100 mL) was added. To the mixture Co2(CO)8 (2,5g, 7,31 mmol, 1,3 eq.) 
was added and it acquired a brown color. This mixture was left stirring for 2 hours, protected 
from the light.  
Then DCM (120 mL) and THF (180 mL) were added to the solution. This solution was cooled 
in an ice bath. Then was added to the mixture NMO (7,90 g, 6,74 mmol, 1,2 eq). This reaction 
was left stirring for 20 hours. 
The reaction mixture was filtered through SiO2 and washed with 20% EtOAc/Hexane and 
concentrated in the rotavapor. 
To purify the compound a flash chromatography (4*7 cm) was done using as eluent 1% 
EtOAc/Hexane. The compound was then concentrated in the rotavapor and identified by 
NMR (1H, 13C and 13C-DEPT).  
Aspect: yellow oill 
Ƞ = 67% 
RF = 0,48 (5% EtOAc/Hexane)  
1H NMR (400 MHz, CDCl3) δ 7.21 – 6.85 (5H, m,HPh), 3.19 – 3.07 (1H, m, H-7), 2.70 – 2.47 
(3H, m), 2.34 (1H,d, J = 13.5 Hz, CH2Si), 2.25 (1H, d, J = 13.4 Hz, CH2Si), 2.15 (1H, d, J = 
16.9 Hz, H-7a), 1.88 (2H, m, H-1), 1.36 (3H,m), 0.90 (9H,s, t-Bu), 0.23 (6H, s, Si-Me2), 0.07 
(3H,s, CH3-Si), 0.06 (3H, s, CH3-Si 
13C NMR (101 MHz, CDCl3) δ 213.1 (C, C-2), 189.4 (C, C-3a), 140.3 (C, C-3), 136.4 (C), 
128.38 (2*CH2, CPh) 128.15 (2*CH2, CPh), 124.10 (C, CPh), 77.76 (CH, C-7), 52.88(CH, C-
7a) 41.00 (CH2), 35.16(CH2), 30.5(CH2), 25.90 (3*CH3, t-Bu), 25.52 (CH2), 23.82 (CH2), 
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18.09 (C, t-Bu), -2.01 (CH3, CH3-Si), -2.17 (CH3, CH3-Si), -3.82 (CH3, CH3-Si), -4.48 (CH3, 
CH3-Si) 
2.2.9. Resolution attempt 1 
 
To a 25 mL round bottom flask 6 (0,07 g, 0,3 mmol, 1 eq), EtOAc (10 mL) and z-Ala-
OSu (0,08 g, 0,3 mmol, 1 eq) were added. Then was added a catalytic quantity of DMAP.  
The crude was then concentrated and purified by chromatographic SiO2 column (8*2 cm). 
As eluent was used 25 % EtOAc/Hexane.  
Aspect: yellow oil 
RF = 0,42 (20 % EtOAc/Hex) 
2.3. Bicyclic ring 5,5 
2.3.1. Synthesis of 2-(pent-4-yn-1-yloxy)tetrahydro-2H-pyran 
(15) 
 
To a 100 mL reaction tube dried and filled with argon, compound 14 (7,94 mL, 84 
mmol, 1 eq) was added. Then PPTS (1,06 g, 4,2 mmol, 0,05 eq.), DHP (11,50 mL, 126 
mmol, 1,5 eq.) and dried DCM (100 mL) were added. This mixture was left stirring for 17 
hours.  
Then the mixture was transferred to a separation funnel and a saturated solution of NAHCO3 
(40 mL) was added. The organic layer was extracted using DCM (3 *16 mL) and washed 
with water and a saturated solution of NaCl (20 mL). Then was dried, filtrated and 
concentrated in the rotavapor.  
The crude was purified by SiO2 column and as eluent Et2O/hexane was used. This was then 
filtered and concentrated in the rotavapor.  
Aspect: yellow oil  
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Rf = 0,70 (20% AcOEt/Hex) 
2.3.2. Synthesis of benzyldimethyl(5-((tetrahydro-2H-pyran-
2-yl) oxy)pent-1-yn-1-yl) silane (16) 
 
 
To the compound 15 THF (80 mL) was added. This mixture was cooled and a 
solution of n-BuLi in hexane (100 mL, 101 mmol, 1,2 eq.) was added. This mixture was left 
stirring for 30 minutes. To the reaction mixture SiBuMe2Cl (17,09 mL, 109 mmol, 1,3 eq.) 
was added and was left stirring for 22 hours. The mixture was cooled at 0°C and an aqueous 
solution of HCl (60 mL, 1M) was added. The mixture was transferred to a separation funnel 
and the organic layer was extracted with Et2O (3*20 mL) and washed with a saturated 
solution of NaCl. Then the organic layer was dried with sodium sulfate, filtered and 
concentrated in the rotavapor and used directly in the next step.  
Aspect: yellow oil 
RF = 0,94 (20% AcOEt/Hex) 
2.3.3. Synthesis of 5-(benzyldimethylsilyl)pent-4-yn-1-ol (17) 
 
To the obtained mixture 80 mL of MeOH, and p-TsOH (1,20 g, 6,3 mmol, 0,075 eq.) 
were added. The mixture was left stirring for about two and a half hours.  
To stop the reaction Et3N (≈ 0,88 mL, 0,075eq.) was added. The mixture was concentrated 
in the rotavapor, and then transferred to a separation funnel. The organic layer was washed 
with a saturated solution of NaCL (1*30 mL) and then extracted with CH2Cl2 (3*20 mL). The 
organic layer was then dried with sodium sulfate, filtered and concentrated in the rotavapor. 
The crude was purified by a column of SiO2 column (10,5*5 cm). To elute the pretended 
compound first was used only hexane, and then the polarity was gradually increased with 
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the use of Ethyl acetate, by 5% Ethyl acetate in hexane, and then 10% ethyl acetate in 
Hexane.  
Then was made another column in which was used the same eluents as above, hexane, for 
the first fraction, then 5% ethyl acetate in hexane and lastly 10% ethyl acetate in hexane. 
This product was then identified by RMN (1H, 13C and 13C-DEPT). The yield was 85%, for 
the three steps (1.3.1, 1.3.2 and 1.3.3). Was obtained a yellow oil. 
Aspect: yellow oil 
Ƞ = 85% 
Rf = 0,37 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (5H, m, HPh), 3.71 (2H, t, J = 6.1 Hz, H-1), 2.34 
(2H, t, J = 6.9 Hz, H-3), 2.17 (2H ,s, CH2Si), 1.81 – 1.66 (3H, m, H-2 and OH), 0.11 (6H, s, 
Si-Me2) 
2.3.4. Synthesis of 5-(benzyldimethylsilyl)pent-4-ynal (18) 
 
In a dried and protected with argon reactor dried DCM (≈400 mL), NaOAc (6,74g, 
82,1 mmol, 1,15 eq.) and the PCC (30,94g, 143 mmol, 2 eq.) were added, then carefully the 
compound 17 was added. This mixture was left stirring for two and a half hours. In this 
procedure we used 12 grams of SiO2 instead of the molecular sieves. This reaction, initially 
orange, changed the color to a very dark brown in the end of the reaction.  
The mixture was filtered through SiO2 to a bottom round flask, washed with Et2O and 
concentrated. Then the mixture was transferred, under argon, to a dried Schlenk flask and 
was concentrated. 
Aspect: yellow oil 
Rf = 0,69 (20% AcOEt/Hex) 
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2.3.5. Synthesis of 7-(benzyldimethylsilyl)hept-1-en-6-yn-3-
ol (19) 
 
To a protected with argon Schlenk flask, containing the mixture from the previous 
reaction THF (≈160 mL) was added and using a cannula a solution of Vinylmagnesium 
bromide in THF (≈120 mL, 107mmol, 1,5 eq.) was added at -78 °C. The mixture was left 
stirring at room temperature for 16 hours. Then to the reaction a saturated solution of NH4Cl 
(30 mL) and NaCl (30 mL) were added. The organic layer was extracted with Et2O (3*30 
mL) and then dried with sodium sulfate, filtered and concentrated in the rotavapor.  
The crude was purified through a SiO2 column (6*8 cm) and was used as a solvent firstly 
only hexane and then 5 % EtOAc/Hex. The obtained yield was 71%.  
Aspect: yellow oil 
Ƞ = 71% 
Rf = 0,54 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.16 (5H, m, HPh), 5.94 – 5.78 (1H, m, H-2), 5.27 (1H, dt, J = 
17.6, 1.4 Hz, H-1), 5.15 (1H, dt, J = 10.4, 1.3 Hz, H-1), 4.24 (1H, dd, J = 12.7, 6.0 Hz, H-3), 
2.44 – 2.28 (2H, m, H-5), 2.19 (2H, s, CH2Si), 2.02 (1H ,s, OH), 1.73 (2H, dd, J = 14.1, 6.9 
Hz, H-4), 0.13 (6H, s, Si-Me2)  
13C NMR (101 MHz, CDCl3) δ 140.47 (CH, C-2), 139.29 (C, CPh), 128.47 (2*CH, CPh), 128.23 
(2*CH, CPh), 124.39 (CH, CPh), 115.17 (CH2, C-1), 108.24 (C, C-7), 83.81 (C, C-6), 72.00 
(CH, C-3), 35.46 (CH2), 26.55 (CH2), 16.25 (CH2), -1.81 (2*CH3, 2CH3-Si). 
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2.3.6. Synthesis of benzyl(5-((tert-butyldimethylsilyl) 
oxy)hept-6-en-1-yn-1-yl)dimethylsilane (20) 
 
To the obtained mixture in the previous reaction imidazole (15,64 g, 230mmol, 4,50 
eq.) and dried DCM (≈350 mL) were added. The mixture was left stirring for 10 minutes. 
After the 10 minutes TBSCl (15,96 g, 106 mmol, 2 eq.) was added. This reaction was 
controlled by TLC. The mixture was transferred to a separation funnel and saturated 
solutions of NaCl (30 mL) and NH4Cl (30 mL) were added. Then the organic layer was 
extracted with DCM (4*30 mL), was dried with sodium sulfate, filtered and concentrated in 
the rotavapor. 
The crude was purified using a chromatographic column with SIO2 (6*8 cm). As eluent was 
firstly used hexane, then 5% EtOAc/Hex and lastly 10% EtOAc/Hex. This reaction had a 
yield of 64 %. This product was then identified by NMR (1H, 13C and 13C-DEPT). A yellow oil 
was obtained. 
Aspect: yellow oil 
Ƞ = 64%. 
Rf = 0,91 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.16 (5H,m, HPh), 5.86 – 5.74 (1H, m, H-6 ), 5.13 (2H, m, H-7), 
4.23 (1H, dd, J = 12.3, 6.2 Hz, H-5), 2.29 (2H, dd, J = 14.7, 7.4 Hz, H-3), 2.19 (2H , s, CH2Si), 
1.77 – 1.63 (2H, m, H-4), 0.91 (9H, s, t-Bu), 0.11 (6H, s, Si-Me2), 0.08 (3H, s, CH3-Si), 0.05 
(3H, s, CH3-Si) 
13C NMR (101 MHz, CDCl3) δ 141.24 (CH, C-6), 139.40 (C, CPh), 128.51 (2*CH, CPh), 128.27 
(2*CH, CPh), 124.41 (CH, CPh), 114.37 (CH2, C-7), 108.79 (C, C-1), 83.31 (C, C-2), 72.45 
(CH, C-5), 36.81 (CH2), 26.66 (CH2), 26.05 (3*CH3, t-Bu), 18.38 (C, C-Si), 16.02 (CH2), -
1.77 (2*CH3, Si-Me2), -4.20 (CH3, CH3-Si), -4.72 (CH3, CH3-Si). 
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2.3.7. Synthesis of 7-(benzyldimethylsilyl)hept-1-en-6-yn-3-
ol (19) 
 
To a 250 mL round bottom flask compound 19 (11,25g, 30,18 mmol, 1 eq.) was 
added. To the flask MeOH (250 mL) and p-TsOH (0,26 g, 0,11 mmol, 0,05 eq.) were added. 
The reaction was left to react for one day.  
The mixture was concentrated in the rotavapor and transferred to a separation funnel. To 
the separation funnel a saturated solution of NaCO3 (100 mL) was added. The organic layer 
was extracted using Et2O, then dried with sodium sulfate and concentrated in the rotavapor. 
The compound was purified by a chromatography column of SiO2 (4*15 cm) and as eluent 
was used firstly 5%EtOAc/Hex, 10%EtOAc/Hex, 20%EtOAc/Hex. The compound was then 
concentrated in the rotavapor and identified by NMR (1H, 13C and 13C-DEPT). This reaction 
had a yield of 89%. 
Aspect: yellow oil 
Ƞ = 89% 
RF = 0,43 (20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.16 (5H, m, HPh), 5.94 – 5.78 (1H, m, H-2), 5.27 (1H, dt, J = 
17.6, 1.4 Hz, H-1), 5.15 (1H, dt, J = 10.4, 1.3 Hz, H-1), 4.24 (1H, dd, J = 12.7, 6.0 Hz, H-3), 
2.44 – 2.28 (2H, m, H-5), 2.19 (2H, s, CH2Si), 2.02 (1H ,s, OH), 1.73 (2H, dd, J = 14.1, 6.9 
Hz, H-4), 0.13 (6H, s, Si-Me2)  
13C NMR (101 MHz, CDCl3) δ 140.47 (CH, C-2), 139.29 (C, CPh), 128.47 (2*CH, CPh), 128.23 
(2*CH, CPh), 124.39 (CH, CPh), 115.17 (CH2, C-1), 108.24 (C, C-7), 83.81 (C, C-6), 72.00 
(CH, C-3), 35.46 (CH2), 26.55 (CH2), 16.25 (CH2), -1.81 (2*CH3, 2CH3-Si). 
. 
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2.3.8. Resolution attempt 2 
 
In a 100 mL round bottom flask 50 mL of DCM and (0,53g, 2,04mmol, 1 eq.) of the 
compound 19 were added. Then the two bases DIEA (0,28g, 2,24 mmol, 1.1 eq.) and DMAP 
(0,27g, 2,24 mmol, 1,1 eq.) were added.  After the mixture was very well dissolved phthalic 
anhydride (0,60 g, 4,08 mmol, 2 eq.) was added. This reaction was left to react for one week 
(the time needed for the starting material almost disappear). Then TBTU (0,66 g, 2,04 mmol, 
1 eq.) was added. This mixture was left for 15 minutes, the time needed to the TBTU became 
dissolved in the mixture. Finally, (R)-Phenylethylamine (0,650mL, 5,1 mmol, 2,5 eq.) was 
added 
Aspect: yellow oil 
RF = 0,40 (dichloromethane) 
2.3.9. Resolution attempt 3 
 
To a round bottom flask 19 (0,52 g, 2 mmol, 1 eq), vinyl acetate (0,090 mL, 0,96 
mmol, 0,49 eq), enzyme Novozyme 435 (0,26 g) and Et2O (15 mL) were added. This reaction 
was left reacting in orbital stirring for 32 hours.  
The mixture was filtrated using Et2O and then concentrated. The obtained crude was 
purified using a SiO2 column (8*15 cm), using dichloromethane as eluent. The compound 
was concentrated and identified by NMR (1H, 13C and 13C-DEPT). 
Aspect: yellow oil 
RF = 0,90-acetilated and 0,50-alchool (dichloromethane) 
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1H NMR (400 MHz, CDCl3) δ 7.25 – 7.02 (5H, m, HPh), 5.78 (1H, m, H-2), 5.36 – 5.30 (1H, 
m, H-3), 5.27 (1H, dt, J = 17.3, 1.3 Hz, H-1), 5.21 (1H, dt, J = 10.5, 1.2 Hz, H-1), 2.28 (2H, 
t, J = 7.4 Hz, H-5), 2.19 (2H, s, CH2Si), 2.07 (3H, s, HAcO), 1.86 (2H, m, H-4), 0.11 (6H, s, Si-
Me2). 
13C NMR (101 MHz, CDCl3) δ 170.17 (C, C=O), 139.27 (C, CPh), 135.84 (CH, C-2), 128.47 
(2*CH, CPh), 128.22 (2*CH, CPh), 124.37 (CH, CPh), 117.27 (CH2, C-1), 107.36 (C, C-7), 
83.79 (C, C-6), 73.64 (CH, C-3), 33.09 (CH2), 26.52 (CH2), 21.24 (CH3,AcO ), 16.02 (CH2), 
-1.87 (2*CH3, 2CH3-Si). 
 
2.3.10. Synthesis of 7-(benzyldimethylsilyl)hept-1-en-6-yn-3-
yl acetate (23) 
 
To a 25 mL round bottom flask 19 (0,50 g, 1,9 mmol, 1 eq), DCM (12mL) and DMAP 
(0,27 g, 2,24 mmol, 1,1 eq) were added. In the end the acetyl chloride was added. This 
reaction was left string and controlled by TLC.  
Then the mixture was purified using an SiO2 column (25*4 cm), and as eluent 
dichloromethane was used. The compound was concentrated and identified by NMR (1H, 
13C and 13C-DEPT). 
Aspect: yellow oil 
Ƞ = 89% 
RF = 0,90 (dichloromethane) 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.02 (5H, m, HPh), 5.78 (1H, m, H-2), 5.36 – 5.30 (1H, 
m, H-3), 5.27 (1H, dt, J = 17.3, 1.3 Hz, H-1), 5.21 (1H, dt, J = 10.5, 1.2 Hz, H-1), 2.28 (2H, 
t, J = 7.4 Hz, H-5), 2.19 (2H, s, CH2Si), 2.07 (3H, s, HAcO), 1.86 (2H, m, H-4), 0.11 (6H, s, Si-
Me2). 
13C NMR (101 MHz, CDCl3) δ 170.17 (C, C=O), 139.27 (C, CPh), 135.84 (CH, C-2), 128.47 
(2*CH, CPh), 128.22 (2*CH, CPh), 124.37 (CH, CPh), 117.27 (CH2, C-1), 107.36 (C, C-7), 
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83.79 (C, C-6), 73.64 (CH, C-3), 33.09 (CH2), 26.52 (CH2), 21.24 (CH3,AcO ), 16.02 (CH2), 
-1.87 (2*CH3, 2CH3-Si). 
2.3.11. Resolution to obtain the alcohol (21) 
 
To a protected with argon Schlenk flask, with molecular sieves compound 19 (1,57 
g, 6,1 mmol, 1eq.), dichloromethane (20 mL) and (+) DIPT (1,80 mL, 7,3 mmol, 1,2 eq) were 
added. This mixture was left stirring at -18,5°C for 30 minutes. Then Ti(iPrO4) (1,50 mL, 6,1 
mmol, 1 eq.) was added and was left string for more 30 minutes. Then TBHP in decane 
(0,80 mL, 5,5 M, 0,7 eq) was added. This mixture was left at -20 °C for 21 days.  
 The reaction was stopped using a mixture of FeSO4.7H2O (3,50 g), tartaric acid (1,14 
g) and H2O (20 mL). The organic layer was extracted with Et2O (3*20 mL). The organic 
layers were combined, dried with sodium sulfate, filtered and then concentrated in the 
rotavapor. Then the crude was purified through flash chromatography (SiO2, 8*15 cm) using 
as eluent 10 % EtOAc/Hexane. The compound was concentrated and identified by NMR 
(1H, 13C and 13C-DEPT). 
Aspect: yellow oil 
RF = 0,70-alcohol (10% EtOAc/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.16 (5H, m, HPh), 5.94 – 5.78 (1H, m, H-2), 5.27 (1H, dt, J = 
17.6, 1.4 Hz, H-1), 5.15 (1H, dt, J = 10.4, 1.3 Hz, H-1), 4.24 (1H, dd, J = 12.7, 6.0 Hz, H-3), 
2.44 – 2.28 (2H, m, H-5), 2.19 (2H, s, CH2Si), 2.02 (1H ,s, OH), 1.73 (2H, dd, J = 14.1, 6.9 
Hz, H-4), 0.13 (6H, s, Si-Me2)  
13C NMR (101 MHz, CDCl3) δ 140.47 (CH, C-2), 139.29 (C, CPh), 128.47 (2*CH, CPh), 128.23 
(2*CH, CPh), 124.39 (CH, CPh), 115.17 (CH2, C-1), 108.24 (C, C-7), 83.81 (C, C-6), 72.00 
(CH, C-3), 35.46 (CH2), 26.55 (CH2), 16.25 (CH2), -1.81 (2*CH3, 2CH3-Si). 
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3. Work done in Spain  
3.1. Bicyclic ring 6,5  
3.1.1. Synthesis of 2-(hex-5-yn-1-yloxy) tetrahydro-2H pyran 
(2) 
 
To a 250 mL round bottom flask compound 1 (15 g, 152 mmol, 1 eq.), dried DCM 
(≈100 mL) and PPTS (1,9 g, 7,64 mmol, 0,05 eq.) were added. This mixture was left to react 
for 3 days. Was formed a clean solution. The mixture then was concentrated in the rotavapor 
and purified using a SiO2 column (5*10 cm). As eluent was used 10% EtOAc/Hex. 
This same experience was repeated. In the total were used 30 grams of the compound 1.  
Aspect: Yellow oil  
RF = 0,80 (20% AcOEt/Hex) 
3.1.2. Synthesis of Synthesis of benzyldimethyl(6-
((tetrahydro-2H-pyran-2-yl) oxy) hex-1-yn-1-yl) silane (3) 
 
Using a cannula compound 2 (32,7 g, 179 mmol, 1 eq.) was transferred to a 500 mL 
round bottom flask, already containing Et2O (200 mL). The mixture was cooled and then was 
slowly added the n-BuLi (79 mL, 197 mmol, 1,1 eq.). This reaction was left stirring 1 hour 
out of the cold bath. The mixture was cooled again at 50 °C and the ClSiMe2Bn was added. 
Then the mixture was taken from the bath and left stirring for 24 hours.  
To stop the reaction some water drops were added. Then the mixture was transferred to a 
separation funnel and was washed with H2O (100 mL) and the organic layer was extracted 
with Et2O (150 mL). The organic layer was dried with sodium sulfate, filtered and then 
concentrated in the rotavapor.  
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To purify the crude a chromatography column of SiO2, (5*14cm) was used and as eluent 
hexane, 5% EtOAc/Hex and lastly 10 % EtOAc/Hex were used.  
This reaction was done again but using 29,45 grams of 2 compound and using as solvent 
THF.  
3.1.3. Synthesis of Synthesis of 6-(benzyldimethylsilyl) hex-
5-yn-1-ol (4) 
 
To a round bottom flask containing 3 (60 g, 181 mmol, 1 eq.) p-TSOH (1,8g; 9,46 
mmol, 0,05eq.) was added. The mixture was left to react for 24 hours, protected from light. 
The mixture was concentrated in the rotavapor and then a saturated solution of sodium 
bicarbonate (5 mL) was added. The mixture was then transferred to a separation funnel, 
and the organic layer was washed with water and extracted with Et2O. 
To purify the crude was necessary to do two chromatography columns of SiO2 (7*20 cm) 
and as eluent 5% EtOAc/Hex and 10%EtOAc/Hex were used.  
This reaction was done again but using 53 grams of the compound 3.  
Aspect: Yellow oil  
RF = 0,38(20% AcOEt/Hex) 
1H NMR (400 MHz, CDCl3) δ 7.44 – 6.86 (5H, m, HPh), 3.59 (2H, t, J = 6.2 Hz, H-1), 2.22 
(2H, t, J = 6.8 Hz, H-4), 2.15 (2H, s, CH2Si), 1.98 (1H, s, OH), 1.68 – 1.47 (4H, m, C-3 and 
C-4), 0.08 (6H, s, Si-Me2) 
13C NMR (101 MHz, CDCl3) δ 139.27 (C, CPh), 128.40 (2*CH, CPh), 128.13 (2*CH, CPh), 
124.28 (CH, CPh), 108.65 (C, C-6), 83.26 (C, C-5), 62.20 (CH2, C-1), 31.73 (CH2), 26.52 
(CH2), 24.84 (CH2), 19.66 (CH2), -1.85 (2*CH3, 2CH3-Si). 
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3.1.4. Synthesis of Ethyl (E)-8-(benzyldimethylsilyl)oct-2-en-
7-ynoate (11) 
 
In a round bottom flask containing the compound 4 (18,9g, 76,7 mmol, 1eq) dried 
DCM (300mL) was added. Then to the solution PhI(OAc)2 (22,72g, 70,54mmol, 0,9 eq.) and 
TEMPO (1,7g, 10 mmol, 0,13 eq.) were added. This mixture was left stirring protected from 
the light for 5 hours. Then to the mixture ylide (24,6 g; 70,54;0,9 eq.) was added. 
The mixture was the transferred to a separation funnel and washed with a saturated solution 
of Na2SO4 (2*150mL). The organic layer was extracted using DCM (3*50 mL). The organic 
layer was dried with sodium sulfate, filtered and concentrated in the rotavapor. 
To purify the crude a chromatography column (5*12 cm) was used and as solvent hexane 
and 5% EtOAc/Hex were used.  
This reaction was done more three times one using 3,3 grams of 4 and the other using 42 
grams of 4.  
Aspect: Yellow oil  
RF = 0,80 (20% AcOEt/Hex) 
Ƞ = 84% 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.04 (5H, m, HPh), 6.94 (1H, m, H-3), 5.84 (1H, dt, J = 
15.6, 1.5 Hz, H-2), 4.20 (2H, q, J = 7.1 Hz, CO2CH2), 2.29 (4H, m, H-4 and H-6), 2.18 (2H, 
s, CH2Si), 1.67 (2H, m, H-5), 1.30 (3H, t, J = 7.1 Hz,CO2CH2CH3), 0.11 (6H, s, Si-Me2). 
13C NMR (101 MHz, CDCl3) δ 166.69 (C, C-1), 148.10 (CH, C-3), 139.32 (C, CPh), 128.48 
(2*CH, CPh), 128.24 (2*CH, CPh), 124.42 (CH, CPh), 122.17 (CH, C-2), 107.83 (C, C-8), 83.93 
(C, C-7), 60.34 (CH2, CO2CH2), 31.11 (CH2), 26.91 (CH2), 26.59 (CH2), 19.43 (CH2), 14.41 
(CH3, CO2CH2CH3), -1.78 (2*CH3, 2CH3-Si).). 
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3.1.5. Synthesis of (E)-8-(benzyldimethylsilyl)oct-2-en-7-yn-
1-ol (12) 
 
 The compound 11 was dried and putted under argon. Then DCM (≈350 mL) was 
added through a cannula. The solution was then cooled in an ice bath and left stirring for a 
little while. Then a solution of DIBAL-H in Hexane (153 mL, 153,4 mmol, 2eq.) was slowly 
added. The mixture was transferred to a separation funnel and a saturated solution of NaCl 
and some drops of HCl 5% were added. Was formed a huge emulsion, very hard to undo. 
The organic layer was extracted with DCM, then was dried with sodium sulfate, filtered and 
concentrated in the rotavapor. 
To purify the crude a chromatography column of SiO2 (5*12) was used and was used as 
eluent first 5% EtOAc/Hex and then 10% EtOAc/Hex. 
Aspect: Yellow oil  
RF = 0,80 (20% AcOEt/Hex) 
Ƞ = 54% 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.04 (5H, m, HPh), 5.76 – 5.60 (2H, m, H-2 and H-3), 
4.19 – 4.01 (2H, m, H-1), 2.24 (2H, t, J = 7.1 Hz, H-6), 2.18 (2H, s, CH2Si), 2.17 – 2.12 (2H, 
m, H-4), 1.65 – 1.56 (2H, m, H-5), 1.43 (1H, s, OH), 0.11 (6H, s, Si-Me2). 
13C NMR (101 MHz, CDCl3) δ 139.40 (C, CPh), 132.15 (CH, C-2), 130.00 (CH,C-3), 128.51 
(2*CH, CPh), 128.24 (2*CH, CPh), 124.39 (CH,CPh), 108.59 (C, C-8), 83.43 (C, C-7), 63.85 
(CH2-C-1), 31.27 (CH2), 28.02 (CH2), 26.66 (CH2), 19.42 (CH2), -1.76 (2*CH3, 2CH3-Si).  
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3.2. Bicyclic ring 5,5, 
3.2.1. Synthesis of Synthesis of 2-(pent-4-yn-1-yloxy) 
tetrahydro-2H-pyran (15) 
 
To a 250 mL round bottom flask compound 14 (20g, 238 mmol, 1 eq.), dried DCM 
(≈200 mL), PPTS (3g, 11,89 mmol, 0,05 eq.) and DHP (30g, 357mmol,1,5eq.) were added. 
This mixture was left to react for 3 days. The mixture was concentrated in the rotavapor and 
purified in a SiO2 column (5*10 cm). As eluent was used 10% EtOAc/Hex. 
This same experience was repeated with 18 grams of 14.  
Aspect: Yellow oil  
RF = 0,70 (20% AcOEt/Hex) 
3.2.2. Synthesis of benzyldimethyl(5-((tetrahydro-2H-pyran-
2-yl) oxy)pent-1-yn-1-yl) silane (16) 
 
Using a cannula compound 15 (33,9 g, 202 mmol, 1 eq.) was transferred to a 500 
mL round bottom flask, already containing Et2O (200 mL). The mixture was cooled and then 
was slowly added the n-BuLi (79 mL, 197 mmol, 1,1 eq.). This reaction was left stirring 1 
hour out of the cold bath. The mixture was cooled again at 50 °C and the ClSiMe2Bn (40,97 
g, 221mmol, 1.1 eq). was added. The mixture was taken from the bath and left stirring for 
24 hours.  
To stop the reaction was added water (10mL). The mixture was concentrated in the 
rotavapor and transferred to a separation funnel and the organic layer was extracted with 
Et2O (150 mL). The organic layer was dried with sodium sulfate, filtered and then 
concentrated in the rotavapor.  
To purify the crude was used a chromatography column of SiO2, (5*14cm), and was used 
as eluent hexane, 5% EtOAc/Hex and lastly 10 % EtOAc/Hex.  
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This reaction was done again but using 38,7 grams of 15 compound. 
Aspect: Yellow oil 
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1H NMR (400 MHz, CDCl3) δ 7.98 – 7.11 (15H, m, Hph), 3.96 (s, 2H, HEt), 
2.87 (1H, s, Hdouble bond), 1.07 (3H, s, HEt). 
  
13C NMR (101 MHz, CDCl3) δ 171.17 (C, C=O), 133.20 – 128.66 (CPh), [60.44 (CH2), 57.90 
(CH2), CEt], [21.12 (CH), 21.11 (CH), Cdoublebond], [14.88 (CH3), 14.28 (CH3), CEt] 
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1H NMR (400 MHz, CDCl3) δ 7.20 – 7.03 (5H, m, HPh), 3.59 (2H, 
t, J = 6.2 Hz, H-1), 2.22 (2H, t, J = 6.8 Hz, H-4), 2.15 (2H, s, 
CH2Si), 1.98 (1H, s, OH), 1.68 – 1.47 (4H, m, C-3 and C-4), 0.08 
(6H, s, Si-Me2). 
 
13C NMR (101 MHz, CDCl3) δ 139.27 (C, CPh), 128.40 (2*CH, CPh), 128.13 (2*CH, CPh), 
124.28 (CH, CPh), 108.65 (C, C-6), 83.26 (C, C-5), 62.20 (CH2, C-1), 31.73 (CH2), 26.52 
(CH2), 24.84 (CH2), 19.66 (CH2), -1.85 (2*CH3, 2CH3-Si). 
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1H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (5H, m, HPh), 5.93 – 
5.82 (1H, m, H-2), 5.24 (1H, dt, J = 17.2, 1.4 Hz, H-1), 5.13 (1H, 
dt, J = 10.4, 1.3 Hz, H-1), 4.14 (1H, q, J = 6.0 Hz, H-3), 2.27 (2H, 
t, J = 6.8 Hz, H-6), 2.18 (2H, s, CH2Si), 1.69 – 1.58 (4H, m,H-4 
and H-5), 1.56 (1H, s,OH), 0.11 (6H,s, Si-Me2).
 
13C NMR (101 MHz, CDCl3) δ 141.14 (CH, C-2), 139.39 (C,CPh), 128.51 (2*CH, CPh), 128.24 
(2*CH,CPh), 124.38 (CH, CPh), 114.97 (CH2, C-1), 108.63 (C, C-8), 83.43 (C, C-7), 72.85 
(CH, C-3), 36.10 (CH2), 26.64 (CH2), 24.45 (CH2), 19.89 (CH2), -1.77 (2*CH3, 2CH3-Si).  
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1H NMR (400 MHz, CDCl3) δ 7.25 – 7.03 (5H, m, HPh), 5.86 – 5.75 
(1H, m, H-7), 5.20 – 5.14 (1H, m, H-8), 5.08 – 5.03 (1H, m, H-8), 
4.14 (1H, q, J = 5.7 Hz, H-6), 2.24 (2H, t, J = 6.5 Hz, H-3), 2.18 (2H, 
s, CH2Si), 1.69 – 1.50 (4H,m, H-4 and H-5), 0.92 (9H,s, t-Bu), 0.10 
(6H, s, Si-Me2), 0.07 (3H, s, CH3-Si), 0.05 (3H, s, CH3-Si). 
 
13C NMR (101 MHz, CDCl3) δ 141.64 (CH, C-7), 139.43 (C, CPh), 128.52 (2*CH, CPh), 128.25 
(2*CH, CPh), 124.37 (CH, CPh), 113.93 (CH2, C-8), 108.92 (C, C-1), 83.16 (C, C-2), 73.49 
(CH, C-6), 37.13 (CH2), 26.69 (CH2), 26.05 (3*CH3, t-Bu), 24.25 (CH2), 20.02 (CH2), 18.41 
(C, C-Si), -1.77 (2*CH3, Si-Me2), -4.23 (CH3, CH3-Si), -4.66 (CH3, CH3-Si). 
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1H NMR (400 MHz, CDCl3) δ 7.21 – 6.85 (5H, m,HPh), 3.19 – 3.07 
(1H, m, H-7), 2.70 – 2.47 (3H, m), 2.34 (1H,d, J = 13.5 Hz, CH2Si), 
2.25 (1H, d, J = 13.4 Hz, CH2Si), 2.15 (1H, d, J = 16.9 Hz, H-7a), 
1.88 (2H, m, H-1), 1.36 (3H,m), 0.90 (9H,s, t-Bu), 0.23 (6H, s, Si-
Me2), 0.07 (3H,s, CH3-Si), 0.06 (3H, s, CH3-Si).  
 
13C NMR (101 MHz, CDCl3) δ 213.1 (C, C-2), 189.4 (C, C-3a), 140.3 (C, CPh), 136.4 (C, C-
3), 128.38 (2*CH2, CPh) 128.15 (2*CH2, CPh), 124.10 (CH, CPh), 77.76 (CH, C-7), 52.88(CH, 
C-7a) 41.00 (CH2), 35.16(CH2), 30.5(CH2), 25.90 (3*CH3, t-Bu), 25.52 (CH2), 23.82 (CH2), 
18.09 (C, t-Bu), -2.01 (CH3, CH3-Si), -2.17 (CH3, CH3-Si), -3.82 (CH3, CH3-Si), -4.48 (CH3, 
CH3-Si) 
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1H NMR (400 MHz, CDCl3) δ 7.24 – 7.04 (5H, m, HPh), 3.71 (2H, t, 
J = 6.1 Hz, H-1), 2.34 (2H, t, J = 6.9 Hz, H-3), 2.17 (2H ,s, CH2Si), 
1.81 – 1.66 (3H, m, H-2 and OH), 0.11 (6H, s, Si-Me2). 
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1H NMR (400 MHz, CDCl3) δ 7.16 (5H, m, HPh), 5.94 – 5.78 (1H, m, 
H-2), 5.27 (1H, dt, J = 17.6, 1.4 Hz, H-1), 5.15 (1H, dt, J = 10.4, 1.3 
Hz, H-1), 4.24 (1H, dd, J = 12.7, 6.0 Hz, H-3), 2.44 – 2.28 (2H, m, H-
5), 2.19 (2H, s, CH2Si), 2.02 (1H ,s, OH), 1.73 (2H, dd, J = 14.1, 6.9 
Hz, H-4), 0.13 (6H, s, Si-Me2)  
 
13C NMR (101 MHz, CDCl3) δ 140.47 (CH, C-2), 139.29 (C, CPh), 128.47 (2*CH, CPh), 128.23 
(2*CH, CPh), 124.39 (CH, CPh), 115.17 (CH2, C-1), 108.24 (C, C-7), 83.81 (C, C-6), 72.00 
(CH, C-3), 35.46 (CH2), 26.55 (CH2), 16.25 (CH2), -1.81 (2*CH3, 2CH3-Si). 
 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
92 
 
 
1H NMR (400 MHz, CDCl3) δ 7.24 – 7.07 (5H,m, HPh), 5.86 – 
5.74 (1H, m, H-6 ), 5.13 (2H, m, H-7), 4.23 (1H, dd, J = 12.3, 
6.2 Hz, H-5), 2.29 (2H, dd, J = 14.7, 7.4 Hz, H-3), 2.19 (2H , 
s, CH2Si), 1.77 – 1.63 (2H, m, H-4), 0.91 (9H, s, t-Bu), 0.11 
(6H, s, Si-Me2), 0.08 (3H, s, CH3-Si), 0.05 (3H, s, CH3-Si). 
 
13C NMR (101 MHz, CDCl3) δ 141.24 (CH, C-6), 139.40 (C, CPh), 128.51 (2*CH, CPh), 128.27 
(2*CH, CPh), 124.41 (CH, CPh), 114.37 (CH2, C-7), 108.79 (C, C-1), 83.31 (C, C-2), 72.45 
(CH, C-5), 36.81 (CH2), 26.66 (CH2), 26.05 (3*CH3, t-Bu), 18.38 (C, C-Si), 16.02 (CH2), -
1.77 (2*CH3, Si-Me2), -4.20 (CH3, CH3-Si), -4.72 (CH3, CH3-Si). 
 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
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1H NMR (400 MHz, CDCl3) δ 7.25 – 7.02 (5H, m, HPh), 5.78 
(1H, m, H-2), 5.36 – 5.30 (1H, m, H-3), 5.27 (1H, dt, J = 17.3, 
1.3 Hz, H-1), 5.21 (1H, dt, J = 10.5, 1.2 Hz, H-1), 2.28 (2H, t, 
J = 7.4 Hz, H-5), 2.19 (2H, s, CH2Si), 2.07 (3H, s, HAcO), 1.86 
(2H, m, H-4), 0.11 (6H, s, Si-Me2).
 
13C NMR (101 MHz, CDCl3) δ 170.17 (C, C=O), 139.27 (C, CPh), 135.84 (CH, C-2), 128.47 
(2*CH, CPh), 128.22 (2*CH, CPh), 124.37 (CH, CPh), 117.27 (CH2, C-1), 107.36 (C, C-7), 
83.79 (C, C-6), 73.64 (CH, C-3), 33.09 (CH2), 26.52 (CH2), 21.24 (CH3,AcO ), 16.02 (CH2), 
-1.87 (2*CH3, 2CH3-Si). 
 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
94 
 
 
1H NMR (400 MHz, CDCl3) δ 7.25 – 7.04 (5H, m, HPh), 6.94 (1H, m, 
H-3), 5.84 (1H, dt, J = 15.6, 1.5 Hz, H-2), 4.20 (2H, q, J = 7.1 Hz, 
CO2CH2), 2.29 (4H, m, H-4 and H-6), 2.18 (2H, s, CH2Si), 1.67 (2H, 
m, H-5), 1.30 (3H, t, J = 7.1 Hz,CO2CH2CH3), 0.11 (6H, s, Si-Me2). 
 
13C NMR (101 MHz, CDCl3) δ 166.69 (C, C-1), 148.10 (CH, C-3), 139.32 (C, CPh), 128.48 
(2*CH, CPh), 128.24 (2*CH, CPh), 124.42 (CH, CPh), 122.17 (CH, C-2), 107.83 (C, C-8), 83.93 
(C, C-7), 60.34 (CH2, CO2CH2), 31.11 (CH2), 26.91 (CH2), 26.59 (CH2), 19.43 (CH2), 14.41 
(CH3, CO2CH2CH3), -1.78 (2*CH3, 2CH3-Si).). 
 
 
FCUP 
Synthesis of precursors of new analogs of the vitamin D changed in the bicyclic ring CD 
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1H NMR (400 MHz, CDCl3) δ 7.25 – 7.04 (5H, m, HPh), 5.76 – 5.60 (2H, 
m, H-2 and H-3), 4.19 – 4.01 (2H, m, H-1), 2.24 (2H, t, J = 7.1 Hz, H-
6), 2.18 (2H, s, CH2Si), 2.17 – 2.12 (2H, m, H-4), 1.65 – 1.56 (2H, m, 
H-5), 1.43 (1H, s, OH), 0.11 (6H, s, Si-Me2). 
 
13C NMR (101 MHz, CDCl3) δ 139.40 (C, CPh), 132.15 (CH, C-2), 130.00 (CH,C-3), 128.51 
(2*CH, CPh), 128.24 (2*CH, CPh), 124.39 (CH,CPh), 108.59 (C, C-8), 83.43 (C, C-7), 63.85 
(CH2-C-1), 31.27 (CH2), 28.02 (CH2), 26.66 (CH2), 19.42 (CH2), -1.76 (2*CH3, 2CH3-Si).  
 
